



This is a repository copy of *Phosphopeptide enrichment for phosphoproteomic analysis - a tutorial and review of novel materials*.

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/163272/>

Version: Accepted Version

---

**Article:**

Qiu, W., Evans, C.A. [orcid.org/0000-0003-4356-9216](https://orcid.org/0000-0003-4356-9216), Landels, A. et al. (2 more authors) (2020) Phosphopeptide enrichment for phosphoproteomic analysis - a tutorial and review of novel materials. *Analytica Chimica Acta*, 1129. pp. 158-180. ISSN 0003-2670

<https://doi.org/10.1016/j.aca.2020.04.053>

---

Article available under the terms of the CC-BY-NC-ND licence  
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

---

1	Contents	
2	Phosphopeptide enrichment for Phosphoproteomic Analysis - A Tutorial and Review of Novel	
3	Materials.....	1
4	Abstract.....	3
5	1. Introduction.....	3
6	1.1 Biological significance of protein phosphorylation.....	3
7	1.2 Phosphoproteomics: Technical challenges and the need for p-peptide enrichment.....	5
8	1.3 Overview of a phosphoproteomic workflow – key steps.....	6
9	1.4 Current practice for p-peptide enrichment.....	6
10	1.5 Scope for improvement.....	7
11	2. Tutorial for phosphoproteomic analysis-general workflow design.....	8
12	2.1 Starting with a question.....	8
13	2.2 Experimental/process design.....	9
14	2.3 Planning.....	9
15	2.4 Extraction.....	10
16	2.5 Protein digestion.....	11
17	2.6 Fractionation.....	13
18	2.7 P-peptide enrichment.....	15
19	2.8 Mass Spectrometry.....	16
20	2.9 Data Analysis.....	17
21	3. Strategies for improving p-peptide enrichment.....	18
22	3.1 Buffers.....	18
23	3.2 P-peptide enrichment – optimization strategies.....	20

---

24	3.3 Improving phosphoproteome coverage .....	31
25	4. Summary and Perspectives .....	38
26	References .....	42
27	Figure Legends .....	52
28		
29		

---

30 **Phosphopeptide enrichment for Phosphoproteomic Analysis - A Tutorial and Review of**  
31 **Novel Materials**

32 Wen Qiu<sup>1,\*</sup>, Caroline Evans<sup>2,\*</sup>, Andrew Landels<sup>2</sup>, Trong Khoa Pham<sup>2</sup>, Phillip C. Wright<sup>3,#</sup>

33

34 <sup>1</sup>State Key Laboratory of Rice Biology, Ministry of Agriculture Key Lab of Molecular  
35 Biology of Crop Pathogens and Insects, Institute of Biotechnology, Zhejiang University,  
36 Hangzhou 310058, China

37

38 <sup>2</sup>ChELSI Institute, Department of Chemical and Biological Engineering, The University of  
39 Sheffield, Mappin Street, Sheffield, S1 3JD, United Kingdom

40

41 <sup>3</sup>School of Engineering, Faculty of Science, Agriculture and Engineering, Newcastle  
42 University, Newcastle upon Tyne NE1 7RU, United Kingdom

43 \*: Equally contributed.

44 #: Correspondence to P.C.W. Phillip.Wright@newcastle.ac.uk

45 **Abbreviations used in the paper:**

46 Post-translational modifications (PTMs), mass spectrometry (MS), liquid  
47 chromatography (LC), tandem MS (MS/MS), phosphopeptide (p-peptide), label-free  
48 quantification (LFQ), stable isotope labelling by amino acids in cell culture (SILAC),  
49 Tandem Mass Tags (TMT) isobaric tags for relative and absolute quantification (iTRAQ),  
50 phospho-serine (pSer), threonine (pThr), tyrosine (pTyr), immobilized metal ion affinity  
51 chromatography (IMAC), metal oxide affinity chromatography (MOAC), acetonitrile  
52 (ACN), sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS-PAGE), filter  
53 assisted sample preparation (FASP), solid phase extraction (SPE), high performance  
54 liquid chromatography (HPLC), reverse phase (RP), strong cation exchange (SCX),  
55 electrostatic repulsion hydrophilic interaction chromatography (ERLIC), solution  
56 isoelectric focusing (sIEF), strong anion exchange (SAX), histidine (pHis), arginine (Arg),

---

57 lysine (Lys), aspartate (Asp), glutamate (Glu), cysteine (Cys), ammonium hydroxide  
58 (NH<sub>4</sub>OH), ammonium bicarbonate (NH<sub>4</sub>HCO<sub>3</sub>), ethylenediaminetetraacetic acid (EDTA),  
59 trifluoroacetic acid (TFA), dihydroxybenzoic acid (DHB), polydopamine (PDA),  
60 iminodiacetic acid (IDA), nitrilotriacetic acid (NTA), phytic acid (PA), polyethyleneimine  
61 (PEI), polydopamine/poly(2-Aminoethyl methacrylate hydrochloride)/arginine  
62 (PAMA-Arg), bovine serum albumin (BSA), isoelectric point (IEP), molybdenum VI oxide  
63 (MoO<sub>3</sub>), graphene oxide (GO), benzenetricarboxylic acid (H3btc),  
64 trimethyl-2-methacryloxyethyl ammonium chloride (META), graphitized carbon black  
65 (GCB), fructose molecular with two phosphate groups (FDP), diphosphorylated  
66 fructose-modified dual-metal-centred zirconium (DZMOF), matrix-assisted laser  
67 desorption ionization (MALDI), graphene aerogel (GA), 1,4,7,10-tetraazacyclododecane  
68 N, N', N'', N'''-tetra-acetic acid (DOTA), polyacrylate (PAA), phosphate-binding molecular  
69 tag chromatography (Phos-tag), polymer-based metal ion affinity capture (PolyMAC),  
70 hydrazide functionalized monodispersed silica microspheres (HFMSM), formic acid (FA),  
71 adenosine tri-phosphate (ATP), molecularly imprinted polymers (MIP), sequential elution  
72 from IMAC (SIMAC), immunoaffinity precipitation (IAP), tandem IMAC (IMAC-IMAC),  
73 magnetic organic framework (MOF), sample-preparation (SP), ion mobility (IM),  
74 electrospray ionization (ESI), p-peptide paper-based analytical devices (phos-PAD), poly  
75 glycidyl methacrylate (PGMA).

---

## 76 **Abstract**

77 Significant technical advancements in phosphopeptide enrichment have enabled the  
78 identification of thousands of p-peptides (mono and multiply phosphorylated) in a single  
79 experiment. However, it is still not possible to enrich all p-peptide species in a single  
80 step. A range of new techniques and materials has been developed, with potential to  
81 provide a step-change in phosphopeptide enrichment. The first half of this review  
82 contains a tutorial for new potential phosphoproteomic researchers; discussing the key  
83 steps of a typical phosphoproteomic experiment used to investigate canonical  
84 phosphorylation sites (serine, threonine and tyrosine). The latter half then show-cases  
85 the latest developments in p-peptide enrichment including: i) Strategies to mitigate  
86 non-specific binding in immobilized metal ion affinity chromatography and metal oxide  
87 affinity chromatography protocols; ii) Techniques to separate multiply phosphorylated  
88 from monophosphorylated peptides (including canonical from non canonical  
89 phosphorylated peptides), or to simultaneously co-enrich other post-translational  
90 modifications; iii) New hybrid materials and methods directed towards enhanced  
91 selectivity and efficiency of metal-based enrichment; iv) Novel materials that hold  
92 promise for enhanced phosphotyrosine enrichment. A combination of well-understood  
93 techniques and materials is much more effective than any technique in isolation; but the  
94 field of phosphoproteomics currently requires benchmarking of novel materials against  
95 current methodologies fully evaluate their utility in peptide based proteoform analysis.

96 **Key words:** phosphoproteoform, canonical and non-canonical phosphorylation,  
97 enrichment, optimization, phosphoproteomics, phosphopeptide

## 98 **1. Introduction**

### 99 **1.1 Biological significance of protein phosphorylation**

100 Reversible phosphorylation is one of the most important post-translational  
101 modifications (PTMs) of proteins occurring in all domains of life [1]. A highly dynamic

---

102 and widespread process, phosphorylation regulates protein 'behaviour in almost every  
103 conceivable way' as noted by in 'The regulation of protein function by multisite  
104 phosphorylation - a 25 year update' by Professor Sir Philip Cohen in 2000 [2].  
105 Phosphorylation essentially acts as a molecular switch, effecting temporal and spatial  
106 changes in protein function [3], with 30% proteins estimated to undergo  
107 phosphorylation [2]. Phosphorylation occurs at single (mono-) or multiple (multi-) sites  
108 and can co-occur with other PTM types to generate different 'proteoforms'.  
109 Phosphoproteoforms form a subset of the 'epiproteome': a term encompassing PTM,  
110 sequence and splice isoform variants encoded by a single gene [4]. Given the key role of  
111 phosphorylation in regulating protein function, global site-specific phosphorylation  
112 analysis provides a mechanistic understanding of cellular processes. The ideal method  
113 would be universal ie characterize all protein phosphoproteoforms within a given  
114 sample or sample set. This analytical approach is termed phosphoproteomic analysis:  
115 with focus on the subset of proteins in the proteome that are subject to  
116 phosphorylation.

117 Current approaches for the analysis of phosphosites predominately employ 'bottom up'  
118 mass spectrometry (MS) based techniques for p-peptide analysis. In this approach  
119 p-peptides are either present endogenously or derived by a proteolytic digestion, step  
120 during sample processing (see Tutorial, section 2.5). Complex mixtures of p-peptides are  
121 analysed in a discovery-focused 'bottom up' approach, which couples liquid  
122 chromatography (LC) with tandem MS (LC-MS/MS). The reader is referred to an article  
123 by Wilson et al, 2018 [5], which explains the principles and key steps of  
124 phosphoproteomic analysis in a way designed to engage readers without prior  
125 knowledge. Discovery phosphoproteomics can operate in quantitative mode for  
126 comparative sample analysis. This is achieved by coupling p-peptide enrichment with  
127 'standard' quantitative proteomic LC-MS/MS workflow coupled to p-peptides  
128 enrichment methods, see Tutorial section 2.8. Quantitative proteomic workflows include  
129 label-free quantification (LFQ), stable isotope labelling by amino acids in cell culture

---

130 (SILAC) or the use of isobaric chemical tags such as Tandem Mass Tags (TMT) and  
131 isobaric tags for relative and absolute quantification (iTRAQ) [6]. To date, the  
132 identification of phospho-serine/threonine (pSer/pThr) sites using MS technique has  
133 improved, but the determination of tyrosine (pTyr) sites is challenging because the  
134 abundance of pTyr is significantly lower than that of pSer/pThr [3]. The field of  
135 phosphoproteomic applications is wide and publications are numerous and thus we  
136 select specific examples to illustrate key principles and developments, signposting to  
137 publications that provide step by step protocols to guide users in the application of  
138 established protocols (see sections 1.4 and 2.7).

### 139 **1.2 Phosphoproteomics: Technical challenges and the need for p-peptide enrichment**

140 The analysis of protein phosphorylation poses significant technical challenges both at  
141 the level of sample preparation, and during the subsequent MS analysis.  
142 Phosphoproteoforms are typically present in low abundance relative to their  
143 non-phosphorylated counterparts, due to the occurrence of phosphorylation at sub  
144 stoichiometric levels in biological samples. Phosphorylated peptides tend to have low  
145 ionisation efficiency due to (i) phosphate groups tending to lose protons to carry  
146 negative charges, and (ii) the background presence of large amounts of  
147 unphosphorylated peptides [6]. Selective phospho-enrichment is thus essential and  
148 critical to success, enabling large-scale phosphoproteomic analysis. P-peptide  
149 enrichment is the first step in phosphorylation site analysis (Fig 1a). Nanoflow LC-MS/MS  
150 and data processing generate both the amino acid sequence (thus protein identity) and  
151 characterization of phosphorylation sites [7]. Data processing can be performed using  
152 publicly or commercially available bioinformatic tools [8, 9]. To support assessing these  
153 datasets, a range of tools that allow visualization of quantitative PTM proteomic  
154 datasets have recently been catalogued and reviewed [10].

---

### 155 **1.3 Overview of a phosphoproteomic workflow – key steps**

156 It is currently possible to identify thousands of different phosphorylation sites within a  
157 single phosphoproteomic experiment. The experimental workflow involves 7 key steps:  
158 1) protein extraction; 2) proteolytic digestion; 3) p-peptide enrichment; 4) fractionation;  
159 5) LC-MS/MS; 6) data analysis; 7) biological inference, as explained in a review article by  
160 Riley and Coon in 2015 [11]. The analysis of protein phosphorylation poses significant  
161 technical challenges both at the level of sample preparation, and during the subsequent  
162 mass spectrometry analysis, as reviewed by Leitner *et al.*, 2016 [7].

### 163 **1.4 Current practice for p-peptide enrichment**

164 Methods employing affinity-based p-peptide enrichment selectively bind the negatively  
165 charged phosphate groups (phosphorylated site) of the p-peptide to metal ions or metal  
166 oxide. These methods are termed Immobilized Metal Ion Affinity Chromatography  
167 (IMAC) and Metal Oxide Affinity Chromatography (MOAC), respectively. There are 3  
168 main steps in the protocol: (1) Incubation: capture of negatively charged phosphate  
169 groups; (2) Washing: removal of non-specific binding. (3) Elution: release of bound  
170 p-peptides (Fig. 1c). Figures showing typical p-peptide enrichment strategies are  
171 included for both IMAC (Fig 2.) and MOAC (Fig 3.)  $\text{Fe}^{3+}$  and  $\text{Ga}^{3+}$  are the most common  
172 ions used for IMAC enrichment, although additional metal ions have emerged over time.  
173 In MOAC,  $\text{TiO}_2$  still is the most commonly used metal oxide, and shows a strong binding  
174 efficiency for p-peptides [14]. The range of metal ions employed for IMAC/MOAC are  
175 detailed in supporting Tables S1A, S1B. Numerous efforts have been directed towards  
176 improving the specificity and sensitivity of IMAC from different aspects. These include  
177 the optimization of operating protocols and the development/testing of novel metal  
178 ions, for efficient binding and effective affinity resins [7, 12, 13].  
179 Elution of p-peptide requires disruption of the binding between the phosphate group  
180 and substrate that is based on reversible Lewis acid-base interaction [12, 13, 19, 20].  
181 Elution of p-peptides from IMAC and MOAC materials is typically achieved by displacing

---

182 the negatively charged phosphate with a high pH, basic buffer, or by incremental  
183 step-wise pH; however, highly acidic solutions have also been employed [18]. When  
184 considering these two approaches, IMAC studies generally result in higher detection of  
185 multi-p-peptides, while TiO<sub>2</sub> enrichment results in a high identification number of  
186 mono-p-peptides. This relative lack of multi-p-peptide enrichment from TiO<sub>2</sub> has been  
187 attributed to the dissociation difficulty and thus incomplete elution of multi-p-peptides  
188 [14].

### 189 **1.5 Scope for improvement**

190 Bioinformatic assessment of the available data indicates that current strategies have not  
191 yet captured all predicted phosphosites, so there is still scope for further improvements  
192 [15]. Protein phosphorylation analysis primarily identifies O-phosphorylated amino  
193 acids, where phosphate binds to the hydroxyl moiety in the  $\gamma$ -group, specifically: pSer,  
194 pThr and pTyr, termed the “canonical” phosphorylation sites. The relative abundance of  
195 these sites within biological samples is typically pSer>PThr>pTyr [2].

196 To ensure comprehensive analysis of biologically relevant phosphorylation events, two  
197 levels of improvements are required – data quantity and data quality. Firstly, the  
198 breadth and frequency of phosphoproteomic studies, whilst increasing, requires  
199 expansion to fill the data gap that will allow a more comprehensive understanding of  
200 phosphoproteome dynamics. To support this, a tutorial is included in section 2 of this  
201 manuscript. This is designed to aid experimental design, preparation, and execution for  
202 new researchers in the field, whilst also providing a reference guide for their own  
203 investigations based on the latest developments in the field described later. Secondly,  
204 the data quality gathered from these studies must be improved; to provide better  
205 quality phosphosite identifications/localizations during proteoform identification from  
206 MS data [16]. This review focuses on improving data quality by reducing the background  
207 sample noise (non p-peptides) through advanced techniques and materials to optimize  
208 the enrichment process. Optimization of the p-peptide enrichment processes can be

---

209 achieved by mitigating non-specific binding, whilst enhancing selectivity (high affinity  
210 towards p-peptides), sensitivity (low starting amounts), robustness (tolerance toward  
211 harsh working conditions), high-throughput (less-time consumption) and reproducibility.  
212 Steps that can be taken to improve the performance of IMAC and MOAC are outlined,  
213 such as working condition optimization, novel carriers or hybrid material synthesis,  
214 along with other new developments.

## 215 **2. Tutorial for phosphoproteomic analysis-general workflow design**

216 This tutorial aims to provide a 'how to guide' for designing a strategy to profile the  
217 phosphoproteome, specifically selecting the most appropriate workflow for a given  
218 sample. The focus is on recent protocols, providing step-by-step descriptions of  
219 procedures, including details of p-peptide enrichment strategy, catalogued in Table 2.  
220 (Table 2). Despite advances, the protocols are generally complex and multi-step, taking  
221 several days to complete – this is exemplified in the study of Mertins *et al.*, 2018 that  
222 describes in depth, parallel processing of the phosphoproteome and proteome using  
223 Ni-NTA IMAC for p-peptide enrichment from human tissue samples [17]. When  
224 considering p-peptide enrichment, improved sensitivity, dynamic range, processing time,  
225 and cost are all practical considerations in workflow adoption. Before beginning  
226 p-peptide analysis, a few key questions should be considered to enable effective  
227 planning and execution.

### 228 **2.1 Starting with a question**

229 As with all proteomic investigations, it should begin with a biological question.  
230 P-peptides present in a sample can be catalogued post enrichment; so combining  
231 p-peptide enrichment with quantitative proteomics enables sample comparison. This  
232 generates relative abundance data and a discovery type proteomics dataset. The new  
233 user should be aware that this dataset will typically be a list of p-peptides and their  
234 associated proteins, likely to contain information on several thousand phosphorylation  
235 sites, with many potential avenues of investigation at the protein level alone – without a

---

236 well-defined investigation this can make the data analysis challenging. It is thus  
237 advisable to define simple and disprovable null hypotheses, then use bioinformatics  
238 resources (section 2.9) to visualise the data and infer biological significance. Once  
239 identified, a p-peptide may be identified to be altered in amount between samples. They  
240 may reflect an increase or decrease in phosphorylation, but may simply reflect altered  
241 protein abundance. Be aware that p-peptide enrichment is accompanied by a loss of  
242 information about the non-phosphorylated proteome component, so studies that  
243 combine proteomic and phosphoproteomic datasets with a high overlap between  
244 protein and phosphoprotein quantifications can be helpful here. A key benefit is  
245 normalization of phosphorylation, which can help account for protein abundance  
246 differences [18].

## 247 **2.2 Experimental/process design**

248 As with other proteomic analyses, experimental design is key, particularly the inclusion  
249 of experimental replicates. It is typical to include 2 or 3 experimental replicates for  
250 proteomic analysis, but it has been noted that overlap between replicates of the  
251 p-peptide enrichment same method can require 4-5 replicates to approach asymptotical  
252 gains in downstream MS analysis [19]. P-peptides typically only make up a small  
253 proportion of total proteomic sample, so enrichment strategies enable and improve  
254 detection. As discussed, be aware that different enrichment strategies can produce a  
255 bias towards p-peptides that contain a single, or multiple, phosphorylation sites and can  
256 therefore create bias or blind-spots in the data. Determining the full range of  
257 phosphoproteins in a sample requires testing and combining of a range of  
258 complementary enrichment protocols.

## 259 **2.3 Planning**

260 With these questions considered, here are a few rules of thumb that will assist practical  
261 planning and execution of a phosphoproteome investigation. In terms of 'how long will it  
262 take': time will vary based on the specifics of the experimental/sample details and

---

263 associated technical challenges; however, a preliminary experimental run to the final  
264 data analysis stage will provide a clear estimate of the minimum requirements. Breaking  
265 this preliminary investigation into the following stages can help track progress towards  
266 the final experimental procedure: Extraction; Protein digestion; Peptide fractionation;  
267 Enrichment; Mass Spectrometry and Data Analysis [11]. A typical phosphoproteomic  
268 experiment can take several days work to prepare samples and the amount of  
269 LC-MS/MS time is dependent on the choice of p-peptide enrichment strategy, the use of  
270 sample fractionation (see sections 2.6, 2.7). The choice of quantitative proteomic  
271 analysis method influences MS run time, see section 2.8 [20].

## 272 **2.4 Extraction**

273 The first test to perform is absolute protein quantification from extraction. A trial of this  
274 is advisable even if the 'best' procedure for the organism/biological system has already  
275 been identified.

276 (1) Lysis. Chemical or physical lysis methods can effectively fracture cells, these can  
277 include one or a combination of sonication, liquid nitrogen grinding, bead-beating, or  
278 boiling in surfactant. Some cell types pose specific technical challenges, for which  
279 customised protocols are often available, for example for plant tissues [21]. Samples can  
280 be degraded rapidly at room temperature, so all treatment processes should be  
281 performed on ice. Protease and phosphatase inhibitors are critical for preventing protein  
282 and phosphorylation loss, so these must be included in the lysis buffer [22].  
283 Phosphate-rich nucleic acids reduce sample quality, so inclusion of nucleases such as  
284 benzonase is beneficial [8].

285 (2) Contaminants. Be aware of potential contaminants: for example - phospholipids,  
286 photosynthetic pigments, and secondary metabolites in plant tissues produce  
287 interference that increases the sample complexity, reducing efficiency and specificity of  
288 p-peptide enrichment [21]. Sample clean-up is therefore important for improving the  
289 data quality, with the associated benefit of reducing maintenance of LC-MS/MS

---

290 equipment. As a general clean-up consideration, p-peptide enriched samples must  
291 ultimately be compatible with the downstream LC-MS/MS analysis ie. free of salts and  
292 detergents [4]. Total protein can be precipitated using acetone, acetonitrile (ACN) [5], or  
293 methanol/chloroform [8] for 2 h or overnight at -20 °C

294 (3) How much protein? In general, a larger amount of protein will assist in the detection  
295 of very low abundance p-peptides, and provide more flexibility in the enrichment  
296 process. Typical starting amounts are 0.1 - 5 mg total protein for enrichment [23], but  
297 protocols have been developed to enrich for sub-femtomole level p-peptides from cell  
298 line and human tissue samples where samples are amounts are limited. A protocol  
299 applicable to picograms of starting material, is that applied to human leukocyte antigen  
300 class I p-peptides [24]. Protein concentration can be determined using traditional  
301 protein assays, for example, the Bicinchoninic Acid assay which can be applied to  
302 analysis of either proteins or peptides, as required by the user [17]. Note that not all  
303 traditional protein assay reagents are compatible with common interferences such as  
304 detergents and buffer components used in sample preparation for phosphoproteomic  
305 analysis.

306 (4) Quality at a glance. Evaluation of protein sample quality, amount and complexity can  
307 be simply performed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis: 1D  
308 sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 2D gel  
309 electrophoresis. This also provides a simple one step sample clean up and fractionation  
310 process for GeLC-MS, which can form a component of the SILAC quantitative proteomic  
311 workflow.

## 312 **2.5 Protein digestion**

313 (1) Proteolytic enzymes: Proteins are subject to enzymatic digestion using enzymes -  
314 typically trypsin, Lys-C, Glu-C or Lys-N. Trypsin, alone or in combination with Lys-C, is the  
315 most commonly used cleavage strategy. Trypsin is the most commonly used proteolytic

---

316 enzyme for proteomic and phosphoproteomic analysis, due to its high proteolytic  
317 activity and cleavage specificity C terminal to lysine and arginine. Tryptic (or Lys-C plus  
318 tryptic) peptides possess  $m/z$  values and ionisation characteristics that are well suited to  
319 LC-MS/MS identification.

320 In some cases, digestion with trypsin can be incomplete, particularly for tightly folded  
321 proteins. The presence of a phosphorylation site can also result in missed cleavage,  
322 which impact quantitative accuracy. Use of sequential digestion protocol using Lys-C,  
323 prior to trypsin, results in fewer missed cleavages [25]. Lys-C and Arg-C can also be used  
324 in combination to generate 'tryptic' peptides, but this is not in routine use. It is  
325 interesting to note, that our survey of novel materials (sections 3.2, 3.3), found that of  
326 51 studies employed trypsin or Lys-C, trypsin for testing p-peptide enrichment using  
327 novel enrichment formats. P-peptide discovery, is currently centred on tryptic peptides,  
328 may also be enhanced by the use of alternative proteases. An optimized, robust protocol  
329 suitable for proteolytic digestion by alternative enzymes to trypsin, namely  
330 chymotrypsin, Lys-C, Lys-N, Asp-N, Glu-C or Arg-C has been established [25]. The key  
331 benefits generation of p-peptides with different physico-chemical properties to tryptic  
332 peptides, results in improves coverage (detectability) of the proteome and  
333 phosphoproteome [26]. Sequential enzyme digests, combined with p-peptide  
334 enrichment increase p-peptide coverage, for example Glu-C in combination with trypsin  
335 [27]. There are clear benefits to using alternatives to tryptic digestion.

336 (2) Efficiency of proteolytic digestion: Strategies to assess proteolytic digestion efficiency  
337 include use of 'spike' internal standards and isotope dilution techniques [28, 29]. This is  
338 important because bottom-up proteomics relies on the efficiency and reproducibility of  
339 protein enzymatic digestion. The presence of missed cleavages and nonspecific  
340 cleavages are important sources of variation in protein quantitation. It is important to  
341 note here that phosphorylation of amino acid residues close to trypsin cleavage sites can  
342 influence cleavage efficiency to result in missed cleavage [30]. Missed cleavages are

---

343 sequence context specific [31]. For example, the presence of proline hinders proteolytic  
344 cleavage. A novel enzyme, EndoPro, a proline directed protease that cleaves with high C-  
345 terminal site of proline and alanine residues, with a broad pH range of activity mitigates  
346 this limitation of trypsin. EndoPro, unlike trypsin, has an added advantage of being able  
347 to cleave in the presence of a neighbouring phosphorylation site [32]. As such this  
348 enzyme represents a valuable addition to the protease 'toolkit' for p-peptide enrichment  
349 workflows.

350 (3) Modes of proteolytic digestion: This sample processing step can be performed in gel,  
351 in solution or alternatively using filter assisted sample preparation (FASP). In gel and  
352 FASP strategies offer the advantage of sample 'clean up' during the digestion protocol.  
353 As an example, FASP has been applied for removal of nucleic acids, phospholipids,  
354 photosynthetic pigments, and secondary metabolites from plant tissues as part of the  
355 universal plant phosphoproteomic workflow [21].

356 (4) Sample clean up: typically performed at the peptide level, both before and after  
357 p-peptide enrichment, to ensure compatibility with MS analyses. Materials such as C18,  
358 graphite carbon and Hexagonal boron nitride are typically used for solid phase  
359 extraction (SPE) for enriching and desalting of peptides with a range of physicochemical  
360 properties. The performance of boron nitride is comparable to combined C18 and  
361 graphite carbon material, as discussed in a review article discussing protocols used for  
362 sample clean up procedures in proteomics [33].

## 363 **2.6 Fractionation**

364 Sample complexity can be reduced by high performance liquid chromatography (HPLC)  
365 separation at the peptide level [14, 15]. Peptides derived from complex samples  
366 particularly benefit from an independent ie 'offline' pre-fractionation step, in addition to  
367 the fractionation 'online' (also termed 'hyphenated') or 'coupled' to LC-MS/MS. The  
368 'offline' fractionation step should be orthogonal to the traditional 'online' nano flow

---

369 reverse phase (RP)-HPLC employed in LC-MS/MS to ensure that different  
370 physico-chemical properties are exploited for maximum reduction in sample complexity.  
371 Since reversed phase 'online' fractionation is based on hydrophobicity, 'offline'  
372 fractionation typically uses charge based separation. In terms of 'best practice', a  
373 comparison of strong cation exchange (SCX), electrostatic repulsion hydrophilic  
374 interaction chromatography (ERLIC), and solution isoelectric focusing (sIEF) fractionation  
375 upstream of RP-LC-MS/MS analysis (in terms of identified p-peptide numbers) indicated  
376 SCX-LC-MS/MS > sIEF-LC/MS-MS > ERLIC-LC-MS/MS. There was partial overlap in the  
377 type of p-peptide and phosphosites, identified between methods, but also populations  
378 of p-peptides unique to each fractionation type, indicating complementarity [9].

379 Chromatographic materials are available in both column ( $\text{ml min}^{-1}$  flow rates) and  
380 tip-based format. Dehghani and co-authors evaluated different fractionation strategies  
381 following  $\text{TiO}_2$  treatment for p-peptide enrichment, including column-based SCX (the  
382 most commonly used SCX approach), pipette tip-based SCX, concatenated high-pH  
383 reversed-phase (basic-RP), and column-based strong anion exchange (SAX). SCX  
384 methods produced higher observations of p-peptides than either basic-RP or SAX; with  
385 SAX showing a greatly reduced number of phosphosite relative to basic-RP [8].  
386 Fractionation of p-peptides using pipette tip-based columns leads to similar results as  
387 the common approach using liquid chromatography-based methods-[8]. The number of  
388 observed p-peptides from the pipette tip-based SCX were comparable with the number  
389 detected using the column-SCX method, but with the advantage of greatly reduced cost,  
390 time and complexity. Basic-RP is popular due to high peak capacity, reproducible  
391 retention times, and orthogonality to low-pH RP based separation, and is applied for  
392 peptide fractionation either pre or post p-peptide enrichment [17, 21].

393 'Offline' fractionation reduces sample complexity, which is always beneficial; but it has  
394 limitations. Fractionation requires higher amounts of starting material, and increasing  
395 the number of fractions for LC-MS/MS can lead to diminishing returns on improving the

---

396 quality of the data, at the expense of a linear increase in MS time and associated costs.  
397 While offline fractionation is designed to achieve higher depth of p-peptide coverage ie  
398 more identifications, samples can be run without a pre-fractionation step as a 'single  
399 shot'. It should be noted that in this case that the number of p-peptides may exceed the  
400 analytical capacity (typically 1 microgram) of the nano flow RP-HPLC column [8]. Trial  
401 runs of unfractionated sample can typically be trialled against 5 selected fractions, to  
402 determine the optimal output for the investigation and identify fractions that provide  
403 the highest number of peptides (the typical peptide amount is approximately 1 µg).  
404 There is a great diversity of 'offline' fractionation types and formats, and so it is  
405 recommended that the best methods should be determined empirically to meet  
406 requirements of the study.

407 Recent developments have enabled detection and profiling of p-peptides containing  
408 histidine (pHis) and other non-canonical phospho amino acids (aspartate (Asp), arginine  
409 (Arg), lysine (Lys), glutamate (Glu), cysteine (Cys)) based on selection of buffers that  
410 maintain the acid labile phosphate. This approach, termed UPAX leads to unbiased  
411 p-peptide enrichment strategy for both canonical and non-canonical phosphorylated  
412 peptides using SAX chromatography at near-neutral pH (pH 6.8). This study enabled  
413 identification of 1300 His, Arg, Lys, Asp, Glu and Cys phosphorylation sites [34]. The data  
414 clearly indicated that pHis, Lys and Arg are present at a similar order to the numbers  
415 observed for pTyr under basal conditions in human HeLa cell extracts [34].

## 416 **2.7 P-peptide enrichment**

417 A range of methods are available, of which IMAC, MOAC, PolyMAC and antibody-based  
418 enrichment of PTyr are well established (Fig. 1b). The mode of operation is sequential  
419 steps: peptide capture (including non-specific binding of non p-peptides), washing to  
420 remove non p-peptides and elution of p-peptides (Fig. 1c).

421 Methods for which there are step-by-step guides, with detailed protocols and  
422 information on theoretical and practical aspects are listed with starting amounts of

---

423 material and p-peptide data generated (Table 1). The protocol of Mertins *et al.*, [17], in  
424 common with the other protocols lists, first resuspends proteolytically derived, tryptic  
425 peptides in buffer containing 0.1% trifluoroacetic acid at pH 2, to ensure that the  
426 carboxyl groups of the peptide C termini, glutamic and aspartic acid are protonated. The  
427 negatively charged p-peptides preferentially bind to the resin relative to non p-peptides.  
428 As a general note, performing a test run to establish p-peptide recovery aids  
429 establishment of a method and ensures efficient use of expensive reagents and samples.  
430 The ideal method would efficiently capture all p-peptides in the sample and result in full  
431 recovery of p-peptides from the capture material. New developments in the area are  
432 summarised in Fig 1d and described in detail in section 3.

### 433 **2.8 Mass Spectrometry**

434 (1) A typical LC-MS/MS run time employs 1-3 hours gradients of RP-HPLC operating at  
435 nanoflow rates. A typical sample loading is up to 1 microgram of p-peptide on column.  
436 Evaluating sample loss during the different steps in the sample preparation workflow,  
437 allows the amount of starting materials to be estimated to ensure sufficient p-peptide is  
438 available for analysis.

439 (2) The physical run time of the MS analysis varies, dependent on how complex the  
440 sample is, and the exact running parameters used on the HPLC and MS, as has been  
441 reviewed in depth [11]. In general, label free quantification methods, comparing MS  
442 data between consecutive LC-MS/MS analysis of samples and replicates require more  
443 MS time than methods using multiplex sample analysis eg SILAC (2-3 plex), isobaric  
444 chemical labeling (4, 8 plex iTRAQ, up to 11 plex TMT). The choice of quantitative  
445 phosphoproteomic method also impacts run time, quantitative precision and accuracy  
446 [6].

---

## 447 2.9 MS Data Analysis

448 It is important to ensure that the correct proteomic database is available for database  
449 searching. Database files are typically in FASTA format although this is dependent on the  
450 search engine being used, and long-form database formats can provide additional  
451 information during analysis. These databases can be readily obtained from SwissProt  
452 and NCBI public data repositories for organisms with genome sequence data. Be aware,  
453 if the genome for the organism has not been sequenced and annotated, or if the study is  
454 a metaproteomic analysis, these are both considered advanced investigations with much  
455 more challenging data analysis [35], particularly at the level of PTM [36]. It is advisable  
456 to not perform a first-time phosphoproteomic analysis on these systems unless  
457 advanced bioinformatic support and researcher expertise in phosphoproteomics is  
458 available.

459 A range of computational tools and MS data analysis for p-peptide and site localisation  
460 are available, which are well catalogued and described, alongside proteomic data  
461 analysis pipelines by Paul et al., 2019 [37]. Locard-Paulet *et al* [38] compared 22  
462 pipelines for bottom-up phosphoproteomics analysis involving data base search tools  
463 (MaxQuant, Proteome Discoverer, PeptideShaker), search engines (Andromeda, Comet,  
464 Mascot, MS Amanda, SequestHT, and X!Tandem), and localization scoring algorithms  
465 (delta score, D-score, PTM-score, phosphoRS, and Ascore) for a defined dataset.  
466 Variability in outcomes led to a recommendation to report search and  
467 phospho-localization parameters when publishing datasets, so as to enable accurate  
468 integration of phosphosite assignment from different analysis pipelines. Further  
469 processing for the data, using tools such as the open-access biological pathway  
470 knowledge base Reactome [39] becomes quite specific to the study in question; so  
471 practicing the bioinformatics analysis using a pre-generated dataset from a similar  
472 previous study can be valuable.

---

### 473 3. Strategies for improving p-peptide enrichment

474 This section highlights and discusses the recent improvements to the enrichment  
475 process. It broadly divides these into improvements that focus on the buffers, the  
476 separation matrix materials, and methods to provide enhanced coverage of the  
477 p-proteome.

#### 478 3.1 Buffers

##### 479 3.1.1 pH

480 As the interactions between p-peptides and IMAC/MOAC materials are Lewis acid-base  
481 reactions, pH is a major consideration during the enrichment process. Non-specific  
482 binding of acidic peptides containing aspartate (pI=2.9) and glutamate (pI=3.0) emerged  
483 as a major limitation, as reviewed by Fila and Honys, 2012 [22]. This is caused by the  
484 affinity between the carboxylate moiety on the amino acid  $\gamma$ -group and metal ions  
485 materials emulating the phosphate to metal ion affinity. This non-specific binding can be  
486 reduced by decreasing the pH of loading buffer below the pI of aspartate or glutamate  
487 to remove the negative of charge of acidic residues by protonation. The pH of loading  
488 buffer is a critical consideration, since the number of bound p-peptides will also  
489 decrease at low pH due to protonation of phosphate (pKa=2.12) groups. Thus,  
490 co-purification of acidic peptides and p-peptides is unavoidable [22]. Contamination with  
491 peptides rich in acidic residues is more pronounced in complex biological samples, and  
492 negatively impacts the enrichment efficiency. To prevent the non-specific binding issues  
493 caused by acidic peptides, *O*-methyl esterification can be performed on the acidic  
494 residues; however, the additional steps can result in sample loss through both increased  
495 sample interaction and side reactions [14].

496 The choice of elution buffer and elution method can have a significant impact. A number  
497 of strategies employ a step-wise pH or buffer elution methodology, some recent  
498 examples of these include: 1-5% ammonium solution (pH 10-11, step wise elution);

---

499 bis-Tris propane (pH 11.3); two-step elution (ammonium hydroxide (NH<sub>4</sub>OH) and bis-Tris  
500 propane) [15]; 100 mM ammonium bicarbonate (NH<sub>4</sub>HCO<sub>3</sub>) (pH 9.2-11.3 step gradient  
501 and pH adjust by ammonia) [16]; and 10 mM ethylenediaminetetraacetic acid (EDTA)  
502 buffers [17]. Alternatively, highly acidic solutions such as 1% v/v trifluoroacetic acid  
503 (TFA), pH1.0 [18] have also been employed. The reader is referred to the review article  
504 by Fila and Honys for more theoretical information and a review of traditional IMAC and  
505 MOAC techniques, with a specific focus on optimization of elution buffers for IMAC [22].

### 506 **3.1.2 Optimized buffers for IMAC elution**

507 Obtaining an ideal elution buffer is imperative for efficiently eluting the bound  
508 p-peptides from IMAC resins, and therefore high p-peptide recovery. The ideal elution  
509 buffer should have good elution efficiency (ideally 100%) and should be compatible with  
510 subsequent MS analysis. IMAC-bound p-peptides can be eluted by phosphate containing  
511 buffers 10 mM EDTA, or ammonium hydroxide (pH 10-11) [40]. Optimal ratios of sample  
512 to IMAC material, and the most efficient eluent solution, should be determined  
513 empirically on a case by case basis, depending on small- or large- scale starting  
514 materials.

### 515 **3.1.3 Optimized MOAC buffers**

516 The chemisorption of p-peptides and non-specific binding of acidic peptides is  
517 problematic for MOAC using TiO<sub>2</sub>. Previous efforts have been employed to investigate  
518 the optimized working conditions for buffers. For instance, the application of additive  
519 acids as non-p-peptide inhibitors to solve the strong surface Lewis acidity issues of metal  
520 oxides. Generally, the order of binding interactions with metal oxides of TiO<sub>2</sub> is:  
521 phosphate group > organic acid > carboxyl group [41]. Therefore, the addition of organic  
522 acids competes for binding sites with acidic residues, to reduce non-specific binding and  
523 thus enhance TiO<sub>2</sub> and ZrO<sub>2</sub> p-peptide enrichment specificity [41]. A number of  
524 'non-phosphopeptide- excluding compounds' have been identified, including 2,5-DHB  
525 and phthalic acid [41]. Hydrophilic and soluble glycolic acid and lactic acid were shown

---

526 to be preferable because of better compatibility with LC-MS/MS than 2,5-DHB [42].  
527 Mono p-peptide enrichment is less efficient through using 1M citric acid, which is  
528 possibly caused by its similar binding to TiO<sub>2</sub> beads as mono p-peptides [41]. In general,  
529 the effect of added acids as non-phospho peptides inhibitors has been demonstrated to  
530 vary with the utilized materials [43]. For instance, TiO<sub>2</sub>, ZrO<sub>2</sub>, In<sub>2</sub>O<sub>3</sub> and Fe<sub>2</sub>O<sub>3</sub> showed  
531 significantly improved performance for p-peptides enrichment with the addition of lactic  
532 acid in the loading buffer. In contrast, NiO and SnO<sub>2</sub> exhibited reduced specificity for  
533 p-peptide binding in the presence of lactic acid [43].

534 Furthermore, researchers noted that peptides containing multiple glutamine and  
535 asparagine residues (named N/Q-rich peptides) predominantly co-enriched with  
536 p-peptides by IMAC or TiO<sub>2</sub>, as determined by examination of amino acids distribution  
537 patterns [44, 45]. Notably, the portions of poly-N/Q peptides of non-p-peptides varied  
538 depending on the examined species. Amide containing compounds as buffer modifiers  
539 mitigate N/Q-rich peptides for efficient TiO<sub>2</sub> enrichment. As a result, addition of 125 mM  
540 asparagine and glutamine amino acid amides in the wash buffer (70% ACN, 3% TFA) and  
541 an optimum peptide/TiO<sub>2</sub> ratio (408 µg/mg) [45] resulted in a 30% increase in detected  
542 p-peptides number, as well as a 5-fold decrease in the intensity of non-p-peptides,  
543 without an obvious change in p-peptides intensities [45]. Thus, modifications to buffers  
544 are of proven value in optimization of p-peptide protocols.

## 545 **3.2 P-peptide enrichment – optimization strategies**

### 546 **3.2.1 Optimization of IMAC materials**

#### 547 **3.2.1.1 Development of novel IMAC materials**

548 Novel IMAC formats with high valence metal cation-IMAC such as Ti<sup>4+</sup>, Zr<sup>4+</sup> [46], Nb<sup>5+</sup> [47,  
549 48], Hf<sup>4+</sup> [49], or Sn<sup>4+</sup> [50] have attracted increasing interest due to their high enrichment  
550 efficiency, reusability and relative low detection limit relative to the traditionally used  
551 Fe<sup>3+</sup> or Ga<sup>3+</sup> (supporting Table S1A). Jiang and colleagues compared the enrichment

---

552 efficiency systematically, by coating Fe<sub>3</sub>O<sub>4</sub>@PDA (polydopamine) microspheres with  
553 eight different metal ions. Nb<sup>5+</sup>, Ti<sup>4+</sup> and Zr<sup>4+</sup> showed better selectivity, while Nb<sup>5+</sup>, Ti<sup>4+</sup>  
554 and Ce<sup>4+</sup> displayed higher sensitivity than the other tested materials on tryptic digests of  
555 nonfat milk or β-casein [46]. Thus, Sn<sup>4+</sup> or Nb<sup>5+</sup> were proposed to show similar  
556 performance as Ti<sup>4+</sup> in terms of higher selectivity and enhanced sensitivity [46]. This  
557 agrees well with the previous finding that high valence metal cations present better  
558 p-peptide binding capacity due to a higher coordination number. In addition, the  
559 synthesis of binary metal ions shows promise. For instance, the novel synthesized  
560 Fe<sub>3</sub>O<sub>4</sub>@PDA-Ti/Nb outperforms either single usage or physical mixture format [48].  
561 Notably, it is still unclear how applicable these findings apply to true complex biological  
562 samples, as they were tested on casein protein standards, which are arguably not  
563 representative of all p-peptide types in phosphoproteomic samples.

#### 564 **3.2.1.2 Development of chelating ligands for metal cations immobilization**

565 In addition to testing higher valence metal ions, the method of IMAC can also be  
566 modified by testing different affinity substrate supports and alternative chelating ligands.  
567 Acidic chelating ligands (iminodiacetic acid (IDA), nitrilotriacetic acid (NTA) have mostly  
568 been applied to date. To improve on drawbacks: such as limited specificity and metal  
569 ions loss issues of IDA and NTA; a phosphate group was introduced to immobilize Ti<sup>4+</sup> or  
570 Zr<sup>4+</sup>, but the time-consuming nature of this process limits its more general application  
571 (metal ion immobilization, enrichment, elution) and limits the absorbent surface area.  
572 Moreover, to enhance the poor selectivity caused by the presence of carboxyl groups of  
573 IDA or NTA, alternate IMAC affinity substrates have been rapidly developed (see  
574 supporting Table S1B for representative formats).

575

576 Developments include:

577 (1) The application of graphene with large surface areas and the introduction of a **phytic**  
578 **acid** (PA) molecule provide a benefit due to the presence of six phosphate groups with

---

579 metal ion coordination ability resulting in more affinity sites for IMAC. Moreover, the  
580 excellent hydrophilicity of PA can further reduce non-specific adsorption [51]. Example  
581 formats include MagG@PEI@PA-Ti<sup>4+</sup> [51] (Fig 2a) which yielded a total of 574 p-peptides  
582 from 341 phosphoproteins were detected from 200 µg of HeLa cells using MagG@  
583 @PA-Ti<sup>4+</sup> [51]. The inclusion of polyethyleneimine (PEI), a water soluble polymer  
584 conferred HILIC properties to the IMAC material, enabling binding of N glycopeptides in  
585 addition to p-peptides (see section 3.3.8).

586 (2) Recently, the employment of guanidyl group to modify superparamagnetic SiO<sub>2</sub>  
587 spheres significantly enhance the p-peptide capture specificity, e.g. PAMA-Arg  
588 (polydopamine/poly(2-Aminoethyl methacrylate hydrochloride)/arginine) nanospheres.  
589 With abundant guanidyl and amino groups on these brushes, the newly synthesized  
590 nanospheres exhibited superior selectivity, sensitivity (10<sup>-12</sup> M) and prominent  
591 recyclability (signal intensity of multi-p-peptide remains 80% after 5 cycle usage) for  
592 β-casein as well as biological samples (egg white, non-fat milk and rat brain lysate) [52].

593 (3) **PDA** benefits from the abundant amine and catechol hydroxyl groups it contains,  
594 enabling the coating on diverse surface of organic and inorganic materials through the  
595 self-polymerization of dopamine under a weakly alkaline environment [53], as shown in  
596 Fig 2a-2b. For instance, with high content of Ti<sup>4+</sup> chelated by PDA, Ti<sup>4+</sup>@PDA@GA was  
597 proven to be highly efficient for enriching p-peptides from a mixture of model  
598 phosphoproteins (β-casein) and non-phosphoprotein (bovine serum albumin, BSA), milk  
599 and spiked human serum [53], as shown in Fig 2b.

600 (4) Finally, researchers have pursued development of an easy-to-conduct process to  
601 cope with limited surface area, time consumption cost, and weak coordination.  
602 Compared to the conventional IMAC technique, various micro/nanoparticles including  
603 magnetic core-mesoporous shell variants, mesoporous SiO<sub>2</sub> supported nanocomposites  
604 show promise [54]. On one hand, the synthesized novel sorbents mostly exhibit  
605 excellent performances for p-peptide enrichment due to the intrinsic and robust  
606 magnetic properties, which were beneficial for rapid enrichment and separation of

---

607 p-peptides. Examples include the development of  $\text{Fe}_3\text{O}_4@m\text{SiO}_2\text{-Ti}^{4+}$  [47],  
608  $\text{magG@PDA-Hf}^{4+}$  [49] as indicated in Fig 2c,  $\text{magG@PDA-Sn}^{4+}$  [50], and  
609  $\text{Fe}_3\text{O}_4@\text{SiO}_2@\text{GMA@IDA@Ti}^{4+}$  [55], all of which benefit from the utilization of magnetic  
610 microspheres. On the other hand, the loss of magnetization with the increased number  
611 of shells is not negligible, particularly for those nanostructures using magnetic  
612 core-shells. In addition, interference may be caused by interactions between the  
613 magnetic core and e.g. an acidic  $\text{Ti}^{4+}$  attachment medium [56]. The creation of  
614  $\text{MagSiO}_2@\text{SiO}_2@\text{PDA@Ti(IV)}$  [56] mitigates this since the porous  $\text{SiO}_2$  shell layer was  
615 introduced to protect magnetic core from the acidic medium of  $\text{Ti}^{4+}$  attachment. With  
616 stronger and stable magnetic responsiveness, these microspheres indicate good  
617 (detection limit of 50 fmol/mL) and stable reusability performance on five successive  
618 enrichment cycles for enriching p-peptides from the tested samples of tryptic digests of  
619 a  $\beta$ -casein/BSA mixture and human serum. Although, the drawback is that the synthesis  
620 of these solid supports has been shown to be time-consuming due to the separate  
621 covalent attachment of the functional groups into the sorbent structure, as well as a  
622 tedious post-derivatization process.

623

624 Efforts are developing toward the “green” synthesis of materials, which is  
625 easy-to-conduct and show excellent enrichment performance: sensitivity, selectivity and  
626 robustness.

### 627 **3.2.2 Optimization of MOAC**

628 One of the advantages of MOAC over IMAC is that the oxide form of the ion is more  
629 stable than the metal ion form and has better tolerance to salts, detergents and solvents,  
630 under operational pHs and temperatures, as well as good sensitivity and selectivity [57].  
631 Intensive studies have been performed for p-peptide enrichment using metal oxides  
632 such as listed in supporting Table S2. Key factors affecting MOAC binding performance  
633 (Fig. 1b) towards p-peptides include properties of the material: surface area, pore size,

---

634 isoelectric point (IEP) and magnetic properties, and the presence of additives [43, 58, 59].  
635 Among these, IEP is considered to be the most critical parameter for the enrichment  
636 performance of affinity materials. The widely used  $\text{TiO}_2$ ,  $\text{ZrO}_2$  and  $\text{In}_2\text{O}_3$  have an IEP  
637 around of 6, which has been determined to be optimal for p-peptide enrichment [43].  
638  $\text{TiO}_2$  -based approaches have been widely applied for p-peptide purification, due to  
639 higher selectivity and specificity (in terms of the number of identified p-peptides based on  
640 peptide counts) as well as robustness, amphoteric ion-exchange characteristics, and  
641 tolerance towards many reagents (stable in wide pH ranges) [43, 57].

#### 642 **3.2.2.1 Novel Synthesized Metal Oxides**

643 Commercially available  $\text{TiO}_2$  is the most commonly used material for MOAC, but there  
644 are a number of new metal oxides that show promise. Such materials, include  
645 molybdenum (VI) oxide ( $\text{MoO}_3$ ) nanocomposites coated on graphene oxide ( $\text{MoO}_3/\text{GO}$ )  
646 [60],  $\text{In}_2\text{O}_3$  [43], and 1,3,5-benzenetricarboxylic acid (H3btc) [61]. These oxides can show  
647 greatly enhanced sensitivity to p-peptides, for example H3btc grafted on the PDA-coated  
648  $\text{Fe}_3\text{O}_4$  ( $\text{Fe}_3\text{O}_4@\text{PDA}@\text{Er}(\text{btc})$ ) achieved a detection limit of 20 amol/ $\mu\text{L}$ , and high  
649 efficiency when tested in human serum, making it a very promising candidate for  
650 phosphoproteome research [61].

#### 651 **3.2.2.2 Developments for MOAC -novel ligand supports**

652 As with IMAC, specificity is still a bottleneck for MOAC enrichment, but improvements to  
653 the supporting sorbents can help to address this. A variety of micro/nanostructures have  
654 been developed aimed at high sensitivity and selectivity towards p-peptides. Further  
655 details are available in supporting Table S2. Whilst issues arising from the high Lewis acid  
656 strength of metal oxides can be addressed by application of diverse acids in loading and  
657 washing buffer; the mono p-peptide affinity and “shadow effects” in MOAC may be  
658 caused by the small and deep pores of metal oxide/s. These small crystallites can hinder  
659 the release of p-peptides, as reported for mesoporous  $\text{TiO}_2$  [62], but can be mitigated by

---

660 using synthesized yolk-shell magnetic materials, as observed in  $\text{Fe}_3\text{O}_4@\text{H-fTiO}_2$  (Fig. 3a)  
661 and  $\text{Fe}_3\text{O}_4@\text{H-TiO}_2@\text{f-NiO}$  [62, 63].

662 Supporting composites with high surface area have attracted interest due to their  
663 potential for greatly enhancing the loading capacity, which contributes improved  
664 p-peptide enrichment. Examples include coordination with GO, for  
665 GO-trimethyl-2-methacryloxyethyl ammonium chloride-titania monolithic column  
666 ( $\text{GO-META-TiO}_2$ ) [64] and  $\text{F-TiO}_2\text{-GO}$  (Fig. 3b) [65]. Supporting resins with high surface  
667 area also result in higher p-peptides coverage, favour the isolation of large p-peptides,  
668 and lead to the detection of high number p-peptides with higher abundance. For  
669 instance, the application of graphitized carbon black ( $\text{mGCB@TiO}_2$ ) led to 48%  
670 enrichment coverage (p-peptides / total peptides), elution of 10% of the common  
671 p-peptides and favours detection of p-peptide >3 KDa, while commercial spin column  
672 resulted in the detection of 40% enrichment coverage but only 1% high abundant  
673 p-peptides, with p-peptide <2.5 KDa [66]. Another example is  $\text{Fe}_3\text{O}_4@\text{H-fTiO}_2$  (yolk-shell  
674 magnetic nanoparticles modified with macro/mesoporous  $\text{TiO}_2$  nanosheets). Compared  
675 to hollow magnetic mesoporous  $\text{TiO}_2$  ( $\text{Fe}_3\text{O}_4@\text{H-mTiO}_2$ ), the high p-peptide enrichment  
676 performance of hollow magnetic macro/mesoporous  $\text{TiO}_2$  nanoparticles ( $\text{Fe}_3\text{O}_4@\text{H-fTiO}_2$ )  
677 is attributed to the high surface area and large pore volume owed by the porous  
678 nanostructure and large hollow space [62].

679 Improvements towards reducing the non-specific adsorption of acidic and other  
680 peptides during MOAC have been developed. One practically demonstrated example is  
681 the introduction of a functional group with high enrichment affinity toward p-peptides  
682 or interface to the metal oxide to eliminate the non-phosphorylated peptides. For  
683 instance, the introduction of a guanidyl-functionalized group into  $\text{TiO}_2$  ( $\text{F-TiO}_2\text{-GO}$ )  
684 improved p-peptide binding for  $\text{TiO}_2$  [65]. Another example is integration of a hydrophilic  
685 fructose-1,6- diphosphate (FDP), which acts as a modifier to regulate the surface  
686 properties of the diphosphorylated fructose-modified dual-metal-centred zirconium

---

687 (DZMOF) that inhibited non-specific binding from other peptides [67]. It is proposed to  
688 benefit from the strong interaction between FDP and metal sites of DZMOF that  
689 produces a high anti-interference performance for eliminating the non-phosphorylated  
690 peptides [67]. This modification is thus an effective development for the enrichment of  
691 p-peptides [67]. The negatively charged surface (pH 5-11) of nanocomposites  
692 PI-Fe<sub>x</sub>O<sub>y</sub>-ZrO<sub>2</sub> was inferred to function (repulsive effect) to reduce the non-specific  
693 adsorption of acidic peptides [68]. Through co-doping of magnetic Fe<sub>x</sub>O<sub>y</sub> partial and ZrO<sub>2</sub>  
694 nanoparticles on polyimide, PI-Fe<sub>x</sub>O<sub>y</sub>-ZrO<sub>2</sub> composite indicate uniform mesopore size of  
695 ca. 3.9 nm, which blocks the entrance of protein but allowing the penetrance of  
696 p-peptides into pore channels, efficiently reducing non-specific protein adsorption [68].  
697 PI-Fe<sub>x</sub>O<sub>y</sub>-ZrO<sub>2</sub> exhibit better adsorption capacities towards the tryptic p-peptides from  
698 human serum or BSA/β-casein mixture: p-peptide signal intensity was increased by  
699 tenfold and a large number of p-peptides detected [68]. In summary, research in this  
700 area has provided significant gains in performance.

701 For ease of flexibility in operation and application, efforts have been directed to provide  
702 materials with wide pH range or elution conditions, highly acidic/alkaline or hydrophobic  
703 conditions tolerance and more efficient p-peptide capture. An example format is  
704 CIM-OH-TiO<sub>2</sub> column (CIMac™ hydroxyl-based analytical column with immobilized TiO<sub>2</sub>  
705 nanoparticles), which offers higher contact area with p-peptides than is achieved using  
706 the traditional macroporous format [69]. Magnetic nanocomposites are attracting  
707 interest from the proteomics researchers; a detailed analysis of their benefits and  
708 limitations is provided by an overview article by Batalha et al [70].

### 709 **3.2.3 Physical configuration considerations**

710 A number of different configurations exist for operating MOAC-TiO<sub>2</sub>, these include spin  
711 column, analytical column, miniaturized column, batch format, nanoparticles, magnetic  
712 beads and p-peptide-affinity MALDI (matrix-assisted laser desorption ionization) plates.  
713 The column treated with manual pipetting is non-magnetic, and continuous mechanical

---

714 manual operation is needed during the enrichment procedure. This is very  
715 labour-intensive, and thus less time efficient. Spin columns are easier to operate than  
716 the manual column format, but are limited by both volume and column clogging issues.  
717 Magnetic format material is generally superior, because of the practical ease of  
718 magnetic separation, the avoidance of packing columns for material preparation, and  
719 much simpler manipulations for the loading, washing, and removal steps. Where  
720 applicable, nanoparticles are more effective than micro-particles due to their higher  
721 surface area. As an example, ZrO<sub>2</sub> packaged tips were shown to be superior to TiO<sub>2</sub> for  
722 mono p-peptide enrichment; however, these differences were found to be negligible  
723 once the material size was comparable [43].

#### 724 **3.2.4 Optimization of composition and structure of carriers and chelates**

725 Efforts have focussed on exploring the diverse composition and structure of carriers and  
726 chelates of the support resins. These include different formats such as magnetic beads,  
727 MALDI plates, columns, tips and gels. In addition, researchers have improved and  
728 optimized diverse reaction conditions for different materials, for instance, the  
729 application of PDA-grafted hybrid magnetic particles for Fe<sub>3</sub>O<sub>4</sub>@PDA-Ti, Fe<sub>3</sub>O<sub>4</sub>@PDA-Nb  
730 or Fe<sub>3</sub>O<sub>4</sub>@PDA-Ti/Nb [48]. For highly efficient enrichment, batch- and tip-based  
731 approaches require further optimization. Developments of new supporting formats are  
732 necessary for enabling high-throughput approaches, due to the multiple manual  
733 handling steps required for these protocols. A few exciting new examples of these  
734 support formats include: the lab-in-syringe mode of Ti<sup>4+</sup>@PDA@GA (graphene aerogel,  
735 GA)[53]; the TiO<sub>2</sub> nanoparticle packed channel array glass microchip [71];  
736 instrument-free TiO<sub>2</sub>-modified filter paper-based analytical device [72]; “green  
737 synthesised” Ti<sup>4+</sup>-IMAC carbonaceous spheres using glucose, vinylphosphonic acid and  
738 water solvent [73] automated p-peptide enrichment and desalting tip set up [74]. All of  
739 these methods are time and cost effective, compared with the commonly used batch  
740 mode or micro-column format packed materials.

---

### 741 3.2.5 Co-doping of metal oxide/ion with metal oxide

742 The synthesis of hybrid materials based on the distinct selectivity of metal ions or metal  
743 dioxides to p-peptides is becoming an area of interest; with a typical diagram of the  
744 p-peptide enrichment strategy shown in Fig. 4.

745 Remarkably, composites containing different metal oxide/ions precursors demonstrated  
746 effective p-peptide enrichment capacity (supporting Table S3, for instance,  
747 TiO<sub>2</sub>/Bi/Fe/Zr [58], B<sub>0.15</sub>F<sub>0.15</sub>TNs [59], and MnFe<sub>2</sub>O<sub>4</sub> MAMSs [75]).

748 Compared to the commercial available TiO<sub>2</sub>, the co-doping of metal (ions Bi<sup>3+</sup>, Fe<sup>3+</sup> and  
749 Zr<sup>4+</sup>) with TiO<sub>2</sub> nanocomposite results in an increased surface area, which leads to a  
750 lower detection threshold for casein/BSA, and a higher detection number of p-peptides  
751 (26% more for HeLa cells using TiO<sub>2</sub>/Bi/Fe/Zr) [58] and phospho-sites (two-fold more for  
752 tissue protein extract from human liver using B<sub>0.15</sub>F<sub>0.15</sub>TNs) [59]. Similarly, the combined  
753 usage of ferric and manganous ions as precursors, in the novel synthesized MnFe<sub>2</sub>O<sub>4</sub>  
754 MAMSs microspheres, showed a higher selectivity for p-peptides than Fe<sub>3</sub>O<sub>4</sub>  
755 nanoparticles or MnOOH nanosheets individually [75]. Similarly, co-fabricating Zr and Ti  
756 simultaneously as a (Zr-Ti)O<sub>4</sub> composite [76], or Al<sub>2</sub>O<sub>3</sub> with either La<sub>2</sub>O<sub>3</sub>, CeO<sub>2</sub>, ZrO<sub>2</sub> or  
757 TiO<sub>2</sub> [77] proved to be superior to the individual metal oxides, demonstrated by their  
758 stronger specificity and higher selectivity for p-peptide enrichment.

759 Synthesized IMAC/MOAC hybrid materials also provide good adsorption capacity, which  
760 improves p-peptides enrichment capacity. This was demonstrated with the magnetic  
761 nanoparticle Fe<sub>3</sub>O<sub>4</sub>@nSiO<sub>2</sub>@mSiO<sub>2</sub>/TiO<sub>2</sub>-Ti<sup>4+</sup> (Fig. 4a), where β-casein p-peptide numbers  
762 were six times higher than Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>; and more p-peptides were identified from  
763 human serum than IMAC (Fe<sub>3</sub>O<sub>4</sub>@nSiO<sub>2</sub>@mSiO<sub>2</sub>/Ti<sup>4+</sup>) or MOAC  
764 (Fe<sub>3</sub>O<sub>4</sub>@nSiO<sub>2</sub>@mSiO<sub>2</sub>/TiO<sub>2</sub>) alone, whilst providing equal detection for peptides with  
765 single and multiple phospho-sites [78]. These nanoparticles are constructed from a  
766 magnetic Fe<sub>3</sub>O<sub>4</sub> core, which is stabilized by a supporting nonporous silica layer (@nSiO<sub>2</sub>).  
767 A mesoporous silica layer (@mSiO<sub>2</sub>) then provides large surface area, to which metal  
768 ions/oxides – in this case TiO<sub>2</sub> and Ti<sup>4+</sup> (/TiO<sub>2</sub>-Ti<sup>4+</sup>) – are chelated by specific linkers.

---

### 769 3.2.6 Efficient coupling molecules for hybrid composites

770 Similar to the optimization on supporting ligands for IMAC or MOAC, enhanced  
771 p-peptide enrichment efficiency can be acquired through the incorporation of different  
772 coupling molecules for hybrid composites. These coupling molecules improve trapping  
773 affinity through improved covalence with metal ions, provision of charge-based  
774 selectivity, or provision of a porous binding environment with high surface area.  
775 Examples of these include: (1) DOTA (1,4,7,10-tetraazacyclododecane N, N', N'',  
776 N'''-tetra-acetic acid), which provides enhanced covalently binding with  $Zr^{4+}$ . The  
777 resulting  $TiO_2@DOTA-Zr$  (Fig. 4b) has demonstrated strong p-peptide trapping affinity  
778 [79]. (2) The coordination of polyacrylate (PAA) with Ti/ $TiO_2$  presents strongly  
779 hydrophilic carboxyl groups for PAA-Ti/ $TiO_2$ , which prevents the non-specific binding  
780 from non-p-peptides [80] and resultant good selectivity. (3) Another example is the  
781 employment of  $TiO_2$  as inner shell and flowerlike NiO as an outer shell for  
782  $Fe_3O_4@H-TiO_2@f-NiO$ . The porous nanostructure and large hollow space endows it with  
783 a high surface area, large pore volume and a better enrichment performance than  
784  $Fe_3O_4@H-TiO_2$  [63]. (4) In addition, contributions from superparamagnetism and ordered  
785 mesoporous channels of (magnetic) graphene into enhanced p-peptide affinities has  
786 been demonstrated for  $G@TiO_2@mSiO_2$  [81] (as shown in Fig. 4c) and  
787  $magG/PD/(Zr-Ti)O_4$  [76].

788 Similar to the novel synthesized particles, the excellent enrichment performances of  
789 hybrid composites is inferred to be: (1) the combined advantages of various materials,  
790 for instance, the dual metal centres of DZMOF containing both inherent Zr-O clusters  
791 and immobilized Zr (IV) contribute greatly to its high selectivity [67]. (2) The increased  
792 surface area and pore volume. (3) The existence of abundant carboxylate groups in the  
793 synthesized materials compared to the single strategy. Disadvantages lie in the limited  
794 surface area and affinity sites caused by the irregular morphology, or single pore  
795 structure generated from the simultaneous reaction of the metal oxides.

---

### 796 **3.2.7 Phosphate-binding molecular tag chromatography (Phos-tag)**

797 The design of Phos-tag is based on the phosphate binding catalytic domain of alkaline  
798 phosphatase. Phos-tag molecules are anchored to a separation gel matrix that peptides  
799 are run through. P-peptide are trapped by the immobilized Phos-tag in the separation  
800 gel, and migrate more slowly than their non-phosphorylated counterparts, allowing  
801 p-peptides and non p-peptides to be separated due to their relative electrophoretic  
802 mobility [82, 83]. Interaction of phospho-sites with the Phos-tag reagent is similar to  
803 IMAC, with application to p-peptides and phosphoproteins [82-84]. Both techniques are  
804 based on the binding between the negative charge of phosphate and positive charge of  
805 ions. P-peptides are captured by the immobilized ions under acidic conditions and eluted  
806 by basic solutions such as ammonium. The major difference between the Phos-tag  
807 workflow and that for IMAC is in the pH aspect. For instance, the working pH for  
808 Phos-tag is alkaline or neutral, while the pH for IMAC is acidic (pH < 3). A benefit of the  
809 Phos-tag approach is the ability to capture both canonical, acid stable phosphorylated  
810 Ser/Thr/Tyr; and non- canonical, acid labile phosphorylation of His/Asp/Lys due to  
811 operation at neutral phosphate. Recently, a small number of p-peptide enrichment  
812 studies have been carried out to improve enrichment efficiency using the Phos-tag  
813 approach under different incubation and elution buffers, such as the exploitation of  
814 Phos-tag-based micropipette-tip format, and the incorporating of two zinc metal ions  
815 into the acrylamide-pendant Zn<sup>2+</sup>-Phos-tag SDS-PAGE [82, 83]. This application of  
816 Phos-tag strategy suffers from limited separation ability and alkaline buffer instability.  
817 Using the Phos-tag as an additive in SDS-PAGE can also enable differentiation of  
818 phosphorylated and non-phosphorylated forms of a protein, as the electrophoretic  
819 mobility is altered due to the binding of the Phos-tag. This also enables separation of  
820 differently phosphorylated proteoforms in proteins with multiple p-sites [85].

---

### 821 **3.2.8 Polymer-based metal ion affinity capture (PolyMAC)**

822 For PolyMAC (polymer-based metal ion affinity capture) technique, p-peptides chelate  
823 to metal ion-functionalized soluble nanopolymer, and thus isolated in a homogeneous  
824 aqueous environment [86]. In brief, this protocol employed the following steps (1) the  
825 ions (e.g. Ti or Fe) were immobilized on soluble polymers for fast chelation; (2) then, the  
826 PolyMAC and p-peptide complexes were covalently coupled to the solid support (e.g.  
827 agarose beads); (3) finally, gel was washed and p-peptides were eluted by using  
828 ammonium hydroxide solution [86]. Compared to the commonly used solid-phase  
829 extraction method for p-peptide capture of IMAC or MOAC, PolyMAC utilize soluble  
830 functionalized dendrimers for p-peptide binding [86, 87]. Previously, a PolyMAC-Ti  
831 technique has been demonstrated to show superior reproducibility for p-peptides  
832 enrichment than IMAC or TiO<sub>2</sub> for cancer samples [11]. Later, PolyMAC enrichment using  
833 Fe demonstrated better selectivity and specificity than Ti, the combined PolyMAC-Ti and  
834 PolyMAC-Fe provided complementary information for B cell phosphoproteomic analyses  
835 [88]. There are also few reports on the use of hydroxyapatite chromatography for  
836 p-peptide enrichment [89]. Although these studies (using Phos-tag, PolyMAC and  
837 hydroxyapatite chromatography) offer some benefits, they have not been widely tested  
838 in complex samples; therefore, their superiorities to IMAC and MOAC at this stage have  
839 not been conclusively demonstrated.

### 840 **3.3 Improving phosphoproteome coverage**

#### 841 **3.3.1 Enhanced multi-p-peptide enrichment**

842 Techniques have been developed for efficient enriching of proteins with high levels of  
843 phosphorylation, specifically peptides containing two or more phosphorylation sites, as  
844 a result of the biological importance of these peptides/proteins [14]. Capturing these  
845 multiple phosphosite peptides is challenging; due to both enrichment material capacity  
846 limits, and the high affinity between enrichment materials and phosphates that result in  
847 incomplete peptide elution [90]. An example of this high affinity, caused by electrostatic

---

848 interactions between  $Ti^{4+}$  and multiple phosphosite peptides, was seen in  
849  $Fe_3O_4@SiO_2-PLP-Ti^{4+}$ , where low recovery rates of multiple phosphosite p-peptides were  
850 observed [91]. Multiple phosphosites on a peptide decrease the IEP; which can affect  
851 how the peptides are eluted. Furthermore, the MS detection and sequencing of these  
852 peptides is limited – particularly in a background of highly abundant non p-peptides and  
853 mono p-peptides. The additional phosphate residues reduce fragmentation efficiency, so  
854 the primary sequence of the peptide can be more difficult to determine; and the  
855 multiply charged peptides have severe suppression of ionization efficiency, which is  
856 caused by the co-existence of high abundance.

857 A selection of techniques has been employed to address multi-phosphorylated peptides  
858 issues, including:

859 (1) Improving operating conditions for conventionally used materials. Bae and  
860 colleagues noticed that selectivity of hydrazide functionalized monodispersed silica  
861 microspheres (HFMSM) [92] towards single or multiple p-peptides varied with the  
862 presence of different concentrations of formic acid (FA) in loading buffers. Lower  
863 pH/high acidity reduces the binding capacity of HFMSM towards both mono p-peptides  
864 and non-specific binding from acidic peptides. A higher concentration (1%, pH 2.4) of FA  
865 favored the enrichment of multiple p-peptides, whilst a lower concentration (0.02%, pH  
866 3.2) promoted detection of both [92].

867 (2) The development of multi-p-peptides high binding capacity materials.  $Ti^{4+}$  ions have  
868 affinity towards single p-peptides, while mixed  $Ni^{2+}/Zn^{2+}$ ,  $Ga^{3+}$  and  $Nb^{5+}$  ions show a  
869 preference for multi p-peptides. Compared to  $Ti^{4+}$ -ATP (adenosine tri-phosphate)-MNPs,  
870  $Ga^{3+}$ -ATP-MNPs [93] was demonstrated to have higher selectivity and improved  
871 coverage (30% more) towards multi p-peptides from the tested rat liver mitochondria. It  
872 is speculated to be caused by the highly hydrophilic surface, where the immobilized  $Ga^{3+}$   
873 provides suitable chelating strength for multi p-peptides, e.g.  $Fe^{3+}$ -IMAC gel vs  
874  $Fe_3O_4@SiO_2-PLP-Ti^{4+}$  [91]. Interestingly, simultaneous analysis of mono- and multi-

---

875 p-peptides is possible through the use of cerium-based nanocomposites: P-CCF (PEG–  
876 Ce/CeO<sub>2</sub>–Fe<sub>3</sub>O<sub>4</sub>) can be used to extract mono p-peptides, and a CSF (Ce/CeO<sub>2</sub>–  
877 SO<sub>4</sub><sup>2-</sup>/Fe<sub>2</sub>O<sub>3</sub>) probe can selectively enrich multiple p-peptides [94]. This technique  
878 benefits from the tight interactions between positively charged metal ions (Fe<sup>3+</sup> and Ce<sup>4+</sup>)  
879 and the negatively charged phosphate group; and de-phosphorylation catalysed by CeO<sub>2</sub>  
880 [94].

881 (3) Design and introduction of multiple phosphate recognition units. Multi p-peptide  
882 enrichment for Zn<sup>2+</sup>-dipicolylamine complex-coated magnetic microspheres (ZnMMs) is  
883 enhanced due to both the large number of binuclear ZnDpa (the artificial receptor)  
884 binding sites, and a strong magnetic responsiveness on the microsphere's surface [95].  
885 Another example is the introduction of hydrogen bonding smart copolymer, which can  
886 modulate the adsorption/desorption of multi-p-peptides on enrichment material [90].  
887 Most of these techniques that have been applied have been limited to the  
888 determination of peptides containing 2 or 3 phosphosites [14].

889 (4) Decreasing nonspecific binding through hydrophobic interactions. This can be  
890 achieved through the introduction of phosphate ion pre-coordinated Ti<sup>4+</sup>-IMAC [96]. The  
891 application of hydrazide, the amine-based functional group, aids the capture of  
892 p-peptides through electrostatic attraction and hydrogen bonding [92]; phosphoric  
893 acid-modified DZMOF showed improved selectivity toward multi p-peptides from both  
894 model proteins ( $\alpha$ - and  $\beta$ -casein); and complex biological mixtures, where the  
895 identification number was increased from 605 (18.6%) to 1871 (70.1%) in HeLa cell  
896 lysate digests [67].

897 (5) Combined usage of different materials or approaches. This approach is unavoidable  
898 as a benchmarking technique, as the overlapping p-peptides ranged from 59% to 79%  
899 when using the same materials for independent experiment, and jointly identified  
900 p-peptides only ranged between 16% and 52% when different MOAC materials were  
901 applied [43]. Individually, TiO<sub>2</sub> shows higher affinity than phosphotyrosine selective

---

902 molecularly imprinted polymers (MIP) under identical experimental conditions [85].  
903 However, TiO<sub>2</sub> has certain limitations; for instance, it shows a bias towards identification  
904 of mono p-peptides, which will result in the incomplete information for the multi  
905 p-peptide section of the data. In addition, the matrix components of MOAC may hinder  
906 the successful purification of p-peptides, as pointed in the study of human whole blood  
907 samples or acute myeloid leukemia samples, where Ti<sup>4+</sup>-IMAC and Fe<sup>3+</sup>-IMAC  
908 outperforms either TiO<sub>2</sub> beads, spin columns, or the graphitized carbon black-TiO<sub>2</sub>  
909 composite [97] toward multiple p-peptide detection. Thus, the combined application of  
910 IMAC and TiO<sub>2</sub> termed SIMAC (sequential elution from IMAC) was reasonable [14].  
911 Briefly, to increase the identification coverage of multiple p-peptides, the acidic and  
912 IMAC flow-through elution, which contains non-p-peptides and mono-p-peptides, were  
913 pooled and submitted for further TiO<sub>2</sub> treatment, while the basic elution was analysed  
914 directly by LC-MS/MS [14]. Although SIMAC leads to more identification of multiple  
915 p-peptides [44], low enrichment efficiency from SIMAC (possibly due to the poor  
916 performance of MOAC) using an acute myeloid leukemia sample was found [44, 98].

917 In conclusion, combining the advantages of different techniques, e.g. SIMAC strategy [14]  
918 or the synthesis of hybrid materials, the binary materials are promising for providing  
919 complementary phosphoproteomic information because of the excellent affinity  
920 towards both single- and multiple- p-peptides.

### 921 **3.3.2 Michael addition**

922 Compared to affinity-based enrichment methods, chemical modifications have high  
923 specificity [7]. There are a range of chemical modifications available, including  
924 β-elimination, carbodi-imide condensation, oxidation-reduction condensation, and  
925 α-Diazo resin; which all functionally replace the phosphate group with another chemical  
926 group that can be targeted specifically. A typical example of this is β-elimination, in  
927 which the phosphate group of phospho -serine or -threonine is eliminated through the  
928 addition of basic solvents containing Ba<sup>2+</sup> or Ca<sup>2+</sup>, or cations of the lanthanide group [7].

---

929 This process is coupled with the addition of propanedithiol (the Michael addition), which  
930 covalently binds to thiols and introduce free SH groups for enrichment. Phosphate  
931 elimination during MS analysis prevents neutral loss, retains the intact peptide  
932 sequence-which is useful for identification - and increases the ionization efficiency for  
933 MS positive ion mode [99]; however, chemical treatments can result in both sample loss,  
934 due to multiple reaction steps, and the increase in sample complexity resulting from  
935 incomplete and side reactions [7].

### 936 **3.3.3 Anti-tyrosine antibodies**

937 As mentioned above, pTyr sites make up a smaller fraction of the p-proteome, and are  
938 often under-represented due to sampling bias. Commercially available anti-tyrosine  
939 antibodies have a high affinity for pTyr and can be used for selective enrichment of pTyr  
940 peptides; but poor reproducibility, low sensitivity, and limited availability/variability of  
941 antibody/bulk starting materials limit enrichment capacity - particularly for complex  
942 peptide mixtures [100], and high costs limit their wider application [101]. To solve the  
943 affinity specificity and quantification accuracy issue caused by sequence bias, pTyr  
944 antibody cocktails (combined different pTyr antibodies together) have been proposed  
945 [102]. A replacement biological-capture method has also been reported: where a pTyr  
946 super-binding protein domain, created by introducing 3 point mutations into the pTyr  
947 binding pocket of the pTyr binding SH2 domain of the Src protein, captures the pTyr  
948 peptides, which are then eluted using a competitive elution agent, biotin-pYEEI  
949 (pTyr-Glu-Glu-Ile) [101]. This technique, however, is limited by the biotin-pYEEI used to  
950 elute pTyr from the SH2 super-binder, as it must be removed from the sample before  
951 LC-MS/MS analysis. The additional purification step results in significant sample loss  
952 [103]. The low recovery of these biological enrichment methods limits their applications  
953 to untreated cells or tissue samples with much lower pTyr levels.

---

#### 954 **3.3.4 Incorporation of phosphate recognition artificial receptors**

955 Compared to conventionally used ligands, the incorporation of the binuclear  
956  $Zn^{2+}$ -dipicolylamine complex-coated ZnDpa as a phosphate-selective artificial receptor,  
957 greatly improved the p-peptide enriched efficiency [95]. As a result, the detection limit  
958 through using ZnDpa was 250 fmol for  $\beta$ -casein. Advances of ZnDpa are high affinity and  
959 specificity toward phosphate groups, contributing to the resolution of non-specific  
960 binding from acidic or basic residues issues [95]. The introduction of artificial receptors  
961 with the incorporation of materials with multiple binding sites may shine light on the  
962 interpretation of comprehensive phosphoproteome research. However, this enrichment  
963 testing was only carried out towards p-peptides from tryptic digests of standard proteins  
964  $\beta$ -casein/BSA, and as mentioned above, requires further validation with true (more  
965 realistic) biological samples.

#### 966 **3.3.5 IMAC or MOAC with antibody-based treatment**

967 Possemato et al. reported that only less than 5% overlapped phospho-sites were  
968 obtained upon the application of  $TiO_2$  and immunoaffinity precipitation (IAP) with  
969 different antibodies (pY-, pAKT/AMPK-, pATM/R-, and pST) treatment, which indicate a  
970 pS:pT:pY ratio approximated at 90:10:<1 for  $TiO_2$ , but 51:29:20 for IAP data [104]. The  
971 low overlap between IMAC, MOAC and pTyr antibody has also been observed elsewhere  
972 [15], indicating the importance of a combined strategy. The SH2 super-binder  
973 enrichment strategy has been combined with IMAC with  $Ti^{4+}$ -IMAC [103], and an  
974 updated one-step SH2 super-binder method [105], as well as in a biphasic affinity  
975 chromatography approach, where Src SH2 super-binder was coupled with NeutrAvidin  
976 affinity chromatography, which resulted in enhanced specific selectivity [106].

#### 977 **3.3.6 Use of IMAC in combination with other techniques**

978 Previously, the incorporation of  $TiO_2$  with SIMAC has been found to improve the  
979 phosphoproteome coverage [107]. Further, the application of combining of different  
980 IMAC metals: (tandem IMAC: IMAC-IMAC) or the combining of IMAC with other

---

981 p-peptide enrichment techniques (e.g. Fe-IMAC with p-peptide precipitation by CaCl<sub>2</sub>,  
982 pTyr phosphotyrosine immunoprecipitation and methyl esterification, as well as  
983 β-elimination) have been proven to be superior to the one step IMAC enrichment  
984 approach [14].

### 985 **3.3.7 MOAC-TiO<sub>2</sub> with other techniques**

986 The combination of phosphotyrosine-imprinted polymer with TiO<sub>2</sub> (pY-MIP-TiO<sub>2</sub>) shed  
987 light on the study of pThr and pTyr, based on the finding that pY-MIP-TiO<sub>2</sub> protocol  
988 caused comparable identification numbers with TiO<sub>2</sub> alone, with enhanced ion signal  
989 intensities for pThr and pTyr, but not pSer [100]. Moreover, the incorporation of  
990 alternative β-elimination followed by the Michael approach is required for the precise  
991 assignment about the location of multisite-phosphorylated (especially higher than  
992 triply-phosphorylated peptides) Ser/Thr-rich regions after the MS detection of p-peptides  
993 using TiO<sub>2</sub> treatment [108], for which the presence of high number of phosphorylated  
994 residues on the same peptide decrease the IEP and thus challenge MS sequencing and  
995 detection. In addition, the combination of conventional TiO<sub>2</sub> with novel developed  
996 hydrogen bonding-based polymeric material was recommend for p-peptides enrichment  
997 [90], from which the latter may facilitate the discovery of high proportions of pThr and  
998 pTyr, particularly from multi-p-peptides.

### 999 **3.3.8 Simultaneous detection of p-peptides and other PTMs**

1000 Phosphorylation and glycosylation are of the most ubiquitous PTMs, which are highly associated  
1001 with various biological processes. Previous studies demonstrate crosstalk between the two PTMs  
1002 [109], and so efforts have been made to improve the simultaneous detection of phosphorylation  
1003 and other PTM, for example glycopeptides. A typical diagram of p-peptide and glycopeptide  
1004 enrichment is shown in Fig. 5. Co-enrichment can be achieved either through using materials  
1005 with various capabilities for different PTMs enrichment, or through fabricating nanomaterials  
1006 that possess properties of both p-peptide enrichment (IMAC or MOAC) and glycopeptide  
1007 enrichment by using affinity-based materials. These materials are shown in Table S4, and include

---

1008 amino functioned [110], hydrophilic interaction liquid chromatograph for hydrophilic interaction  
1009 [111], and boronic acid affinity for SPIOs@SiO<sub>2</sub>@MOF (boronic acid-functionalized magnetic  
1010 organic framework Zr-MOF nanocomposites, as shown in Fig. 5a) [112]. The good  
1011 biocompatibility, excellent hydrophilic property and a large amount of Ti<sup>4+</sup> endows the *de novo*  
1012 synthesis of nanomaterials with great promise for the identification of low abundance N-glyco  
1013 /p-peptides. The material can be ‘tunable’ for p-peptide or N-glyco peptides ie be used for  
1014 simultaneous or independent selection steps using different enrichment conditions, exemplified  
1015 by application MagG@PEI@PA-Ti<sup>4+</sup> to HeLa cell extracts [51].

1016 Other approaches utilize the affinity between glycan chains and TiO<sub>2</sub> or NH<sub>2</sub> hydrophilic  
1017 interaction such as SiO<sub>2</sub>-NH<sub>2</sub>@TiO<sub>2</sub> hollow microspheres [113],  
1018 TiO<sub>2</sub>@SiO<sub>2</sub>-B(OH)<sub>2</sub>@Fe<sub>3</sub>O<sub>4</sub>@ TiO<sub>2</sub> sandwich-like nanosheets [114] (as shown in Fig. 5b),  
1019 Fe<sub>3</sub>O<sub>4</sub>@Au-B(OH)<sub>2</sub>@mTiO<sub>2</sub> core-shell microspheres [115], TiO<sub>2</sub>-NH<sub>2</sub> modified MALDI  
1020 plate (stability and reusability) [116] (Fig. 5c). These enhanced materials will help shed  
1021 new light on phospho- and N-glyco- proteome research.

#### 1022 **4. Summary and Perspectives**

1023 Challenges remain to establish the key goal of a single step enrichment that  
1024 comprehensively captures all p-peptides in a sample, whilst also generating a sample that is  
1025 compatible with LC-MS/MS with minimal processing. As the p-peptide/p-peptide plus other PTM  
1026 enrichment efficiency varies between different techniques, it is strongly recommended that a  
1027 chosen method is necessarily optimized for each new sample. It is important to decide  
1028 on the focus or target of the enrichment in terms of the specific research question, since, in  
1029 terms of current methodologies, “one size” may not fit all. The key conclusion from  
1030 reviewing the latest literature in this field is that phosphoproteomic coverage is  
1031 significantly improved by a combination of different methodologies. Specifically, the  
1032 coverage of enrichments with different materials (ions or oxides) is higher than that for  
1033 replicates with the same material. Hybrid materials synthesized from metal ions/oxides

---

1034 materials synthesized from metal ions/oxides showed excellent enrichment  
1035 performances compared to the component parts. Studies with novel formats are  
1036 provided in Table format (Tables S1-S4) for 51 publications, with information on the  
1037 material, test samples (tryptic or Lys-C, trypsin digests), reported sensitivity and  
1038 selectivity, sample matrix and MS instrumentation. This finding appears to be the result  
1039 of the synthesized composites possessing a relatively higher surface area, good aqueous  
1040 dispersibility, and excellent magnetic responsiveness. Hybrid materials have been  
1041 devised that utilise complementary features, addressing the inherent limitations that  
1042 arise from intrinsic physiochemical properties of existing methods. For example,  
1043 substrate ligands that have stability in strong alkaline and acid buffers, and exhibit  
1044 hydrophilicity to minimize nonspecific binding. Materials using artificial receptors, for  
1045 multiple phosphate-selective binding sites, also show promise.

1046 Identifying the key factors affecting the p-peptide enrichment performance of affinity  
1047 materials has led to optimization of: solvent tolerance, pore size, functional groups, and  
1048 surface area within the materials. Furthermore, through the addition of various organic  
1049 acids as non-p-peptide inhibitors, control of the peptide/enrichment material ratio, and  
1050 use the optimal pH within the elution buffer as process parameters further improves  
1051 enrichment efficiency. The identified parameters are not silver bullet solutions, and  
1052 consideration should to be taken depending on the target of the study – for example,  
1053 the specific affinity of different materials towards p-peptides varies in the presence of  
1054 additives. Despite this, materials are gradually becoming available for unbiased sample  
1055 preparation for protein analysis, such as solid-phase-enhanced sample-preparation (SP3)  
1056 technology. SP3 is a paramagnetic bead-based approach for rapid, robust, and efficient  
1057 processing of protein samples for proteomic analysis. This bead format utilizes  
1058 hydrophilic interaction to mediate exchange or removal of components used for  
1059 proteomic analysis [117]. Use of such materials have potential for widespread adoption,  
1060 due to ease of handling and compatibility with p-peptide enrichment [114].

---

1061 It is important to note that recent developments in MS analysis and peptide spectral  
1062 matching algorithm aid phosphoproteome analysis. The use of ion mobility (IM) MS  
1063 provides additional separation to mass-to-charge ( $m/z$ ) based on structure/shape  
1064 (collisional cross section). IM separations occur at a millisecond timescale and this  
1065 couples effectively with LC-MS to increase separation of co-eluting peptide isomers with  
1066 variant modified sites [99]. The recently developed method for structures for lossless ion  
1067 manipulations ion mobility offers improved sensitivity and separation of p-peptides, in  
1068 particular for resolution of p-peptide isomers, with application to discovery and targeted  
1069 phosphoproteomic workflows [118]. Capillary Electrophoresis, which separates based on  
1070 the size-to-charge ratio of the peptide – with sensitivity to charge state, is well suited to  
1071 the study of PTMs, including phosphorylation. Coupling this approach to MS has brought  
1072 gains in phosphoproteome coverage as exemplified by studies of mouse brain [119] and  
1073 a colon cancer cell line [120].

1074 Novel developed sorbents, especially micro/nanocomposites show great promise for  
1075 phosphoproteomics; however, further exploration is needed before their large-scale  
1076 practical application, due to the very limited data on true biological samples. Current  
1077 data are generally limited towards a “standard” (simple) protein mixture (typically casein  
1078 and BSA), with some limited reference to testing on samples representative of true  
1079 biological samples - HeLa cell lysates or human body fluids (saliva, serum). Tests involve  
1080 mixing of peptides derived from trypsin or Lys-C, trypsin digests of  $\alpha$  and  $\beta$  isoforms of  
1081 caseins/BSA ratio of 1:49 or 1:99 (w/w), selected as representative of the low  
1082 stoichiometry of phosphoproteins typically seen in biological samples such as cell  
1083 lysates. The limitation of this approach is that it lacks the complexity of the p-peptides  
1084 derived from a cellular phosphoproteome. In addition, p-peptides derived from  $\alpha$  and  $\beta$   
1085 casein generally contain acidic residues, are phosphorylated at stoichiometric levels, and  
1086 have a multiple charge state, which limits how representative they are to p-peptides  
1087 found in complex biological samples. Such studies are a good starting point, but are not  
1088 useful for generating generally applicable “rules of thumb”, conclusions gained from

---

1089 experience in different sample types. Many of the novel materials discussed in this  
1090 paper were tested using MALDI sources (Supplementary Tables S1-4); however, ESI  
1091 (electrospray ionization) is the primary ionisation source for many phosphoproteomic  
1092 investigations. Unlike MALDI MS, LC-ESI MSMS is biased toward mono-phosphorylated  
1093 peptides[121], so for representative results it is important that ‘head to head’ method  
1094 comparisons are performed on the same LC-MS/MS system. Phosphoproteomic  
1095 protocols can also benefit from developments in new materials, fractionation protocols  
1096 such as UPAX for canonical and non-canonical p-peptide separation from  
1097 non-phosphorylated peptides [108], widening the scope of phosphoproteomic analysis  
1098 to include acid labile phosphorylation which have been under-reported due to lack of  
1099 detection in pSer/PThr/pY directed workflows [122]. Ultimately, for the new materials  
1100 and processes mentioned here to become widespread and provide true benefit to the  
1101 field of phosphoproteomics, rigorous bench marking is needed against the widespread  
1102 classical methods of p-peptide enrichment currently available; and the ‘winners’ of such  
1103 tests must also be affordable and commercial available.

#### 1104 **Funding**

1105 Wen Qiu was supported by the National Natural Science Foundation of  
1106 China (31801787), China Postdoctoral Science Special Foundation (2018T110600),  
1107 Zhejiang Provincial Postdoctoral Foundation (ZheRenShe [2018] No.73), National Key  
1108 Laboratory Project (2010DS700124-KF1902). Phillip Wright, Caroline Evans and Trong  
1109 Khoa Pham acknowledge financial support from the Engineering and Physical Sciences  
1110 Research Council, the ChELSI initiative (EP/E036252/1). Andrew Landels and Phillip  
1111 Wright acknowledge funding by the European Union Seventh Program for research,  
1112 technical development and demonstration for funding under grant agreement No.  
1113 308518, CyanoFactory.

#### 1114 **Disclosure of interest**

1115 The authors have declared no conflicts of interest.

---

1116 **References**

- 1117 1. Hunter T, *Why nature chose phosphate to modify proteins*. Philos T R Soc B 2012.  
1118 **367**(1602): p. 2513-2516.
- 1119 2. Cohen P., *The regulation of protein function by multisite phosphorylation—a 25*  
1120 *year update*. Trends Biochem Sci, 2000. **25**(12): p. 596-601.
- 1121 3. Olsen JV, et al., *Global, in vivo, and site-specific phosphorylation dynamics in*  
1122 *signaling networks*. Cell, 2006. **127**(3): p. 635-648.
- 1123 4. Smith LM, Kelleher NL, and Consortium for Top Down Proteomics, *Proteform: a*  
1124 *single term describing protein complexity*. Nat Methods, 2013 **10**(3): p. 186-187.
- 1125 5. Wilson GM, et al., *Identifying novel signaling pathways: an exercise scientists*  
1126 *guide to phosphoproteomics*. Exerc Sport Sci Rev 2018. **46**(2): p. 76.
- 1127 6. Potel CM, et al., *Defeating major contaminants in Fe<sup>3+</sup>- immobilized metal ion*  
1128 *affinity chromatography (IMAC) p-peptide enrichment*. Mol Cell Proteomics, 2018.  
1129 **17**(5): p. 1028-1034.
- 1130 7. Leitner A, *Enrichment strategies in phosphoproteomics*. Methods Mol Biol, 2016.  
1131 **1355**: p. 105-121.
- 1132 8. Dehghani A, Gödderz M, and Winter D, *Tip-based fractionation of batch-enriched*  
1133 *p-peptides facilitates easy and robust phosphoproteome analysis*. J Proteome Res,  
1134 2018. **17**(1): p. 46-54.
- 1135 9. Yeh TT, et al., *Comparison of different fractionation strategies for in-depth*  
1136 *phosphoproteomics by liquid chromatography tandem mass spectrometry*. Anal  
1137 Bioanal Chem, 2019 **411**(15): p. 3417-3424.
- 1138 10. Kaur S, et al., *Visualization and analysis of epiproteome dynamics*. J Mol Biol,  
1139 2019. **431**(8): p. 1519-1539.
- 1140 11. Riley NM and Coon JJ, *Phosphoproteomics in the age of rapid and deep proteome*  
1141 *profiling*. Anal Chem, 2016. **88**(1): p. 74-94.
- 1142 12. Peng J and Wu R, *Metal-organic frameworks in proteomics/peptidomics—A review*.  
1143 Anal Chim Acta, 2018. **1027**: p. 9-21.
- 1144 13. Saeed A, et al., *Metal-organic framework-based affinity materials in proteomics*.  
1145 Anal Bioanal Chem, 2019. **411**(9): p. 1745-1759.
- 1146 14. Thingholm TE and Larsen MR, *Sequential elution from IMAC (SIMAC): an*  
1147 *efficient method for enrichment and separation of mono- and multi-phosphorylated*  
1148 *peptides*. Methods Mol Biol, 2016. **1355**: p. 147-160.
- 1149 15. Vlastaridis P, et al., *Estimating the total number of phosphoproteins and*  
1150 *phosphorylation sites in eukaryotic proteomes*. Gigascience, 2017 **6**(2): p. 1-11.
- 1151 16. Qing G, et al., *New opportunities and challenges of smart polymers in*  
1152 *post-translational modification proteomics*. Adv Mater, 2017. **29**(20).
- 1153 17. Mertins P, et al., *Reproducible workflow for multiplexed deep-scale proteome and*  
1154 *phosphoproteome analysis of tumor tissues by liquid chromatography–mass*  
1155 *spectrometry*. Nat Protoc 2018. **13**(7): p. 1632-1661.

- 
- 1156 18. Li J, et al., *Investigation of proteomic and phosphoproteomic responses to*  
1157 *signaling network perturbations reveals functional pathway organizations in Yeast.*  
1158 *Cell Rep*, 2019. **29**(7): p. 2092-2104.
- 1159 19. Matheron L, et al., *Characterization of biases in p-peptide enrichment by*  
1160 *Ti<sup>4+</sup>-immobilized metal affinity chromatography and TiO<sub>2</sub> using a massive*  
1161 *synthetic library and human cell digests.* *Anal Chem*, 2014. **86**(16): p. 8312-8320.
- 1162 20. Hoglebe A, et al., *Benchmarking common quantification strategies for large-scale*  
1163 *phosphoproteomics.* *Nat Commun*, 2018. **9**(1): p. 1045.
- 1164 21. Hsu CC, et al., *Universal plant phosphoproteomics workflow and its application to*  
1165 *tomato signaling in response to cold stress.* *Mol Cell Proteomics*, 2018. **17**(10): p.  
1166 2068-2080.
- 1167 22. Fila J and Honys D, *Enrichment techniques employed in phosphoproteomics.*  
1168 *Amino Acids*, 2012. **43**(3): p. 1025-1047.
- 1169 23. Ruprecht B, et al., *Comprehensive and reproducible p-peptide enrichment using*  
1170 *iron immobilized metal ion affinity chromatography (Fe-IMAC) columns.* *Mol Cell*  
1171 *Proteomics*, 2015. **14**(1): p. 205-215.
- 1172 24. Abelin, J.G., Trantham, P.D., Penny, S.A., Patterson, A.M., Ward, S.T., Hildebrand,  
1173 W.H., Cobbold, M., Bai, D.L., Shabanowitz, J. and Hunt, D.F., *Complementary*  
1174 *IMAC enrichment methods for HLA-associated p-peptide identification by mass*  
1175 *spectrometry.* *Nat Protoc*, 2015. **10**(9): p. 1308.
- 1176 25. Saveliev S, et al., *Trypsin/Lys-C protease mix for enhanced protein mass*  
1177 *spectrometry analysis.* *Nat Methods*, 2013. **10**(11): p. p1134.
- 1178 26. Giansanti P, et al., *An augmented multiple-protease-based human p-peptide atlas.*  
1179 *Cell Rep*, 2015 **11**(11): p. 1834-1843.
- 1180 27. Gilmore JM, Kettenbach AN, and Gerber SA, *Increasing phosphoproteomic*  
1181 *coverage through sequential digestion by complementary proteases.* *Anal Bioanal*  
1182 *Chem*, 2012. **402**(2): p. 711-720.
- 1183 28. Lowenthal MS, et al., *Quantitative bottom-up proteomics depends on digestion*  
1184 *conditions.* *Anal Chem*, 2014. **86**(1): p. 551-558.
- 1185 29. Ji H, et al., *Quantification of cystatin-C in human serum by stable isotope dilution*  
1186 *liquid chromatography electrospray ionization tandem mass spectrometry.* *J*  
1187 *Chromatogr B*, 2017. **1059**: p. 49-55.
- 1188 30. Dickhut C, et al., *Impact of digestion conditions on phosphoproteomics.* *J Proteome*  
1189 *Res*, 2014. **13**(6): p. 2761-2770.
- 1190 31. Gershon PD, *Cleaved and missed sites for trypsin, lys-C, and lys-N can be*  
1191 *predicted with high confidence on the basis of sequence context.* *J Proteome Res*  
1192 2014. **13**(2): p. 702-709.
- 1193 32. van der Laarse SA, et al., *Targeting Proline in (Phospho) Proteomics.* *The FEBS*  
1194 *Journal*, 2019.
- 1195 33. Tubaon RM, Haddad PR, and Quirino JP, *Sample clean-up strategies for ESI mass*  
1196 *spectrometry applications in bottom-up proteomics: trends from 2012 to 2016.*  
1197 *Proteomics*, 2017. **17**(20): p. 1700011.

- 
- 1198 34. Hardman G, et al., *Strong anion exchange-mediated phosphoproteomics reveals*  
1199 *extensive human non-canonical phosphorylation*. The EMBO journal, 2019.  
1200 **38**(21).
- 1201 35. Heyer R, et al., *Challenges and perspectives of metaproteomic data analysis*. J  
1202 Biotechnol, 2017. **261**: p. 24-36.
- 1203 36. Cheng LC, et al., *P-peptide enrichment coupled with label-free quantitative mass*  
1204 *spectrometry to investigate the phosphoproteome in prostate cancer*. JoVE, 2018.  
1205 **138**: p. e57996.
- 1206 37. Paul P, et al., *In silico tools and phosphoproteomic software exclusives*. Processes,  
1207 2019. **7**(12): p. 869.
- 1208 38. Locard-Paulet M, et al., *Comparing 22 popular phosphoproteomics pipelines for*  
1209 *peptide identification and site localization*. J Proteome Res, 2020.
- 1210 39. Jassal B, et al., *The reactome pathway knowledgebase*. Nucleic Acids Res, 2020.  
1211 **48**(D1): p. D498-D503.
- 1212 40. Thingholm TE and Larsen MR, *P-peptide enrichment by immobilized metal affinity*  
1213 *chromatography*. Methods Mol Biol, 2016. **1355**: p. 123-133.
- 1214 41. Jensen SS and Larsen MR, *Evaluation of the impact of some experimental*  
1215 *procedures on different p-peptide enrichment techniques*. Rapid Commun Mass  
1216 Spectrom, 2007. **21**(22): p. 3635-3645.
- 1217 42. Dunn JD, Reid GE, and Bruening ML, *Techniques for p-peptide enrichment prior*  
1218 *to analysis by mass spectrometry*. Mass Spectrom Rev, 2010. **29**(1): p. 29-54.
- 1219 43. Leitner A, S.M., Zimmerli CE, Småt JH., *Insights into chemoselectivity principles*  
1220 *in metal oxide affinity chromatography using tailored nanocast metal oxide*  
1221 *microspheres and mass spectrometry-based phosphoproteomics*. Analyst., 2017  
1222 **142**(11): p. 1993-2003.
- 1223 44. Aasebø E, et al., *Freezing effects on the acute myeloid leukemia cell proteome and*  
1224 *phosphoproteome revealed using optimal quantitative workflows*. J Proteomics,  
1225 2016. **145**: p. 214-225.
- 1226 45. Kanshin E, Michnick SW, and Thibault P, *Displacement of N/Q-rich peptides on*  
1227 *TiO<sub>2</sub> beads enhances the depth and coverage of yeast phosphoproteome analyses*. J  
1228 Proteome Res, 2013. **12**(6): p. 2905-2913.
- 1229 46. Jiang J, et al., *Facile synthesis of Fe<sub>3</sub>O<sub>4</sub>@PDA core-shell microspheres*  
1230 *functionalized with various metal ions: A systematic comparison of commonly-used*  
1231 *metal ions for IMAC enrichment*. Talanta, 2018. **178**: p. 600-607.
- 1232 47. Yao J, S.N., Wang J, Xie Y, Deng C, Zhang X., *Rapid synthesis of*  
1233 *titanium(IV)-immobilized magnetic mesoporous silica nanoparticles for*  
1234 *endogenous p-peptides enrichment*. Proteomics, 2017. **17**(8): p. Epub 2017.
- 1235 48. Jiang J, et al., *Magnetic microspheres modified with Ti(IV) and Nb(V) for*  
1236 *enrichment of p-peptides*. Mikrochim Acta, 2018. **185**(6): p. 309.
- 1237 49. Lin H and Deng C, *Development of Hf<sup>(4+)</sup>-immobilized polydopamine-coated*  
1238 *magnetic graphene for highly selective enrichment of p-peptides*. Talanta, 2016.  
1239 **149**: p. 91-97.

- 
- 1240 50. Lin H, D.C., *Development of immobilized Sn<sup>4+</sup> affinity chromatography material*  
1241 *for highly selective enrichment of p-peptides*. Proteomics, 2016. **16**(21): p.  
1242 2733-2741.
- 1243 51. Hong Y, et al., *Hydrophilic phytic acid-coated magnetic graphene for titanium(IV)*  
1244 *immobilization as a novel hydrophilic interaction liquid*  
1245 *chromatography-immobilized metal affinity chromatography platform for glyco-*  
1246 *and p-peptide enrichment with controllable selectivity*. Anal Chem., 2018.
- 1247 52. Luo B, et al., *PAMA-Arg brushes functionalized magnetic composite nanospheres*  
1248 *for highly effective enrichment of the phosphorylated biomolecules* J Mater Chem B,  
1249 2018. **6**: p. 3969.
- 1250 53. Tan S, et al., *A porous graphene sorbent coated with titanium(IV)-functionalized*  
1251 *polydopamine for selective lab-in-syringe extraction of phosphoproteins and*  
1252 *p-peptides*. Mikrochim Acta. , 2018. **185**(7): p. 316.
- 1253 54. Ramos-Payán M, et al., *Recent advances in sample pre-treatment for emerging*  
1254 *methods in proteomic analysis*. Talanta, 2017. **174**: p. 738-751.
- 1255 55. Capriotti AL, et al., *New Ti-IMAC magnetic polymeric nanoparticles for p-peptide*  
1256 *enrichment from complex real samples*. Talanta, 2018. **178**: p. 274-281.
- 1257 56. Salimi K, et al., *Ti(IV) carrying polydopamine-coated, monodisperse-porous SiO<sub>2</sub>*  
1258 *microspheres with stable magnetic properties for highly selective enrichment of*  
1259 *p-peptides*. Colloids Surf B Biointerfaces, 2017. **153**: p. 280-290.
- 1260 57. Thingholm TE and Larsen MR, *The use of titanium dioxide for selective enrichment*  
1261 *of phosphorylated peptides*. Methods Mol Biol, 2016, . **1355**: p. 135–146.
- 1262 58. Zhu B, et al., *Preparation of TiO<sub>2</sub>/Bi/Fe/Zr nanocomposite for the highly selective*  
1263 *enrichment of p-peptides*. Talanta, 2019. **194**: p. 870-875.
- 1264 59. Zhen D, et al., *Preparation of Bi<sub>0.15</sub>Fe<sub>0.15</sub>TiO<sub>2</sub> nanocomposites for the highly*  
1265 *selective enrichment of p-peptides*. Anal Chem, 2018. **90**(21): p. 12414-12421.
- 1266 60. Sun H, et al., *Facile preparation of molybdenum (VI) oxide – modified graphene*  
1267 *oxide nanocomposite for specific enrichment of p-peptides*. J Chromatogr A, 2017.  
1268 **1521**: p. 36-43.
- 1269 61. Xie Y and Deng C, *Highly efficient enrichment of p-peptides by a magnetic*  
1270 *lanthanide metal-organic framework*  
1271 Talanta, 2016. **159**: p. 1-6.
- 1272 62. Hong Y, et al., *Highly efficient enrichment of p-peptides from HeLa cells using*  
1273 *hollow magnetic macro/mesoporous TiO<sub>2</sub> nanoparticles*. Talanta, 2018. **187**: p.  
1274 223-230.
- 1275 63. Hong Y, et al., *Yolk-shell magnetic mesoporous TiO<sub>2</sub> microspheres with flowerlike*  
1276 *NiO nanosheets for highly selective enrichment of p-peptides*. Nanoscale, 2017.  
1277 **9**(43): p. 16764-16772.
- 1278 64. Zhao S, et al., *GO-META-TiO<sub>2</sub> composite monolithic columns for in-tube*  
1279 *solid-phase microextraction of p-peptides*. Talanta, 2019. **192**: p. 360-367.

- 
- 1280 65. Liu HL and Lian B, *A guanidyl-functionalized TiO<sub>2</sub> nanoparticle-anchored*  
1281 *graphene nanohybrid for enhanced capture of p-peptides*. Rsc Advances, 2018.  
1282 **8**(51): p. 29476-29481.
- 1283 66. Piovesana S, et al., *New magnetic graphitized carbon black TiO<sub>2</sub> composite for*  
1284 *p-peptide selective enrichment in shotgun phosphoproteomics*. Anal Chem, 2016.  
1285 **88**(24): p. 12043-12050.
- 1286 67. Peng J, et al., *Highly specific enrichment of multi-p-peptides by the*  
1287 *di-phosphorylated fructose modified dual-metal centered zirconium-organic*  
1288 *framework*. ACS Appl Mater Interfaces, 2018. **10**(38): p. 32613-32621.
- 1289 68. Wang XM, et al., *ZrO<sub>2</sub> doped magnetic mesoporous polyimide for the efficient*  
1290 *enrichment of p-peptides*. Talanta, 2018. **188**: p. 385-392.
- 1291 69. Černigoj U, et al., *Titanium dioxide nanoparticle coating of*  
1292 *polymethacrylate-based chromatographic monoliths for phosphopeptides*  
1293 *enrichment*. Anal Chim Acta, 2016. **942**: p. 146-154.
- 1294 70. Batalha ÍL and Roque AC, *P-peptide enrichment using various magnetic*  
1295 *nanocomposites: an overview*. Methods Mol Biol, 2016. **1355**: p. 193-209.
- 1296 71. Wang S, et al., *Plasma-assisted alignment in the fabrication of*  
1297 *microchannel-array-based in-tube solid-phase microextraction microchips packed*  
1298 *with TiO<sub>2</sub> nanoparticles for p-peptide analysis*. Anal Chim Acta, 2018. **1018**: p.  
1299 70-77.
- 1300 72. Li L, et al., *Instrument-free enrichment and detection of p-peptides using*  
1301 *paper-based Phos-PAD*. Anal Chim Acta, 2019. **1062**: p. 102-109.
- 1302 73. Zhang HY, et al., *One-step preparation of phosphate-rich carbonaceous spheres*  
1303 *via a hydrothermal approach for p-peptide analysis* Green Chem, 2019. **21**(8): p.  
1304 2052-2060.
- 1305 74. Mullis BT, et al., *Automating complex, multistep processes on a single robotic*  
1306 *platform to generate reproducible phosphoproteomic data*. SLAS Discov, 2019 p.  
1307 2472555219878152.
- 1308 75. Long XY, L.J., Sheng D, Lian HZ., *Spinel-type manganese ferrite (MnFe<sub>2</sub>O<sub>4</sub>)*  
1309 *microspheres: A novel affinity probe for selective and fast enrichment of p-peptides*.  
1310 Talanta., 2017 **166**: p. 36-45.
- 1311 76. Wang M, et al., *Design and synthesis of magnetic binary metal oxides*  
1312 *nanocomposites through dopamine chemistry for highly selective enrichment of*  
1313 *p-peptides*. Proteomics, 2016. **16**(6): p. 915-919.
- 1314 77. Najam-Ul-Haq M, et al., *Alumina nanocomposites: a comparative approach*  
1315 *highlighting the improved characteristics of nanocomposites for p-peptides*  
1316 *enrichment*. Amino Acids, 2016 **48**(11): p. 2571-2579.
- 1317 78. Yang DS, D.X., Min HP, Li B, Su MX, Niu MM, Di B, Yan F., *Design and*  
1318 *synthesis of an immobilized metal affinity chromatography and metal oxide affinity*  
1319 *chromatography hybrid material for improved p-peptide enrichment*. J Chromatogr  
1320 A., 2017. **1505**: p. 56-62.

- 
- 1321 79. Dai J, Wang M, and Liu H, *Highly selective enrichment of p-peptides using*  
1322 *Zr<sup>4+</sup>-immobilized Titania nanoparticles*. *Talanta*, 2017. **164**: p. 222-227.
- 1323 80. Wei XN and Wang HL, *Facile fabrication of hydrophilic PAA-Ti/TiO<sub>2</sub>*  
1324 *nanocomposite for selective enrichment and detection of p-peptides from complex*  
1325 *biological samples*. *Anal Chim Acta*, 2017. **949**: p. 67-75.
- 1326 81. Yao J, et al., *Designed synthesis of Graphene @titania @mesoporous silica hybrid*  
1327 *material as size-exclusive metal oxide affinity chromatography platform for*  
1328 *selective enrichment of endogenous p-peptides*. *Talanta*, 2016. **150**: p. 296-301.
- 1329 82. Yuan ET, et al., *A Phos-tag-based micropipette-tip method for rapid and selective*  
1330 *enrichment of p-peptides*. *Electrophoresis*, 2017. **38**(19): p. 2447-2455.
- 1331 83. Kumar G, *A simple method for detecting phosphorylation of proteins by using*  
1332 *Zn<sup>2+</sup>-Phos-Tag SDS-PAGE at neutral pH*. *Methods Mol Biol*, 2018. **1853**: p.  
1333 223-229.
- 1334 84. Nagy Z, Comer S, and Smolenski A, *Analysis of protein phosphorylation using*  
1335 *Phos-Tag gels*. *Curr Protoc Protein Sci*, 2018. **93**(1): p. e64.
- 1336 85. Chen J, et al., *Validation of molecularly imprinted polymers for side chain selective*  
1337 *p-peptide enrichment*. *J Chromatogr A*, 2016 **1471**: p. 45-50.
- 1338 86. Iliuk AB, et al., *In-depth analyses of kinase-dependent tyrosine phosphoproteomes*  
1339 *based on metal ion-functionalized soluble nanoparticles*. *Mol Cell Proteomics*,  
1340 2010 **9**(10): p. 2162-2172.
- 1341 87. Iliuk A, et al., *In-depth analyses of B cell signaling through tandem mass*  
1342 *spectrometry of p-peptides enriched by PolyMAC*. *Int J Mass Spectrom*, 2015. **377**:  
1343 p. 744-753.
- 1344 88. Arrington JV, et al., *Recent advances in phosphoproteomics and application to*  
1345 *neurological diseases*. *Analyst.*, 2017. **142**(23): p. 4373-4387.
- 1346 89. Caira S, et al., *Simultaneously tracing the geographical origin and presence of*  
1347 *bovine milk in Italian water buffalo Mozzarella cheese using MALDI-TOF data of*  
1348 *casein signature peptides*. *Anal Bioanal Chem*, 2016. **408**(20): p. 5609-5621.
- 1349 90. Qing G, et al., *Hydrogen bond based smart polymer for highly selective and tunable*  
1350 *capture of multiply phosphorylated peptides*. *Nat Commun*, 2017 **8**(1): p. 461.
- 1351 91. Wang Q, et al., *Pyridoxal 5'-phosphate mediated preparation of immobilized metal*  
1352 *affinity material for highly selective and sensitive enrichment of p-peptides*. *J*  
1353 *Chromatogr A*, 2017. **1499**: p. 30-37.
- 1354 92. Xu L, et al., *Hydrazide functionalized monodispersed silica microspheres: a novel*  
1355 *probe with tunable selectivity for a versatile enrichment of p-peptides with different*  
1356 *numbers of phosphorylation sites in MS analysis*. *Chem Commun (Camb)*, 2016. **52**  
1357 (6): p. 1162-1165.
- 1358 93. Zhang L, et al., *Facile synthesis of gallium ions immobilized and adenosine*  
1359 *functionalized magnetic nanoparticles with high selectivity for multi-p-peptides*.  
1360 *Anal Chim Acta*, 2015 **900**: p. 46-55.
- 1361 94. Long XY, et al., *A combination strategy using two novel cerium-based*  
1362 *nanocomposite affinity probes for the selective enrichment of mono- and*

- 
- 1363 *multi-p-peptides in mass spectrometric analysis*. Chem Commun (Camb), 2017.  
1364 **53**(33): p. 4620-4623.
- 1365 95. Bae SW, et al., *Zinc ion-immobilized magnetic microspheres for enrichment and*  
1366 *identification of multi-phosphorylated peptides by mass spectrometry*. Anal Sci,  
1367 2017. **33**(11): p. 1381-1386.
- 1368 96. Liu Z, et al., *Modulating the selectivity of affinity absorbents to multi-p-peptides by*  
1369 *a competitive substitution strategy*. J Chromatogr A, 2016. **1461**: p. 35-41.
- 1370 97. La Barbera G, et al., *Development of an enrichment method for endogenous*  
1371 *p-peptide characterization in human serum*. Anal Bioanal Chem, 2018 **410**(3): p.  
1372 1177-1185.
- 1373 98. Hernandez-Valladares M, A.E., Selheim F, Berven FS, Bruserud Ø., *Selecting*  
1374 *sample preparation workflows for Mass Spectrometry-based proteomic and*  
1375 *phosphoproteomic analysis of patient samples with Acute Myeloid Leukemia*.  
1376 Proteomes., 2016 **4**(3).
- 1377 99. Potel CM, Lemeer S, and Heck AJR, *P-peptide fragmentation and site localization*  
1378 *by mass spectrometry: an update*. Anal Chem, 2019. **91**(1): p. 126-141.
- 1379 100. Bllaci L, et al., *Phosphotyrosine biased enrichment of tryptic peptides from cancer*  
1380 *cells by combining pY-MIP and TiO<sub>2</sub> affinity resins*. Anal Chem, 2017. **89**(21): p.  
1381 11332-11340.
- 1382 101. Bian Y, et al., *Ultra-deep tyrosine phosphoproteomics enabled by a*  
1383 *phosphotyrosine superbinder*. Nat Chem Biol, 2016. **12**(11): p. 959-966.
- 1384 102. Regnier FE and Kim JH, *Proteins and proteoforms: new separation challenges*.  
1385 Anal Chem, 2018. **90**(1): p. 361-373.
- 1386 103. Dong M, et al., *Sensitive, robust, and cost-effective approach for tyrosine*  
1387 *phosphoproteome analysis*. Anal Chem, 2017 **89**(17): p. 9307-9314.
- 1388 104. Possemato AP, P.J., Mulhern D, Guo A, Gygi SP, Beausoleil SA., *Multiplexed*  
1389 *phosphoproteomic profiling using titanium dioxide and immunoaffinity*  
1390 *enrichments reveals complementary phosphorylation events*. J Proteome Res., 2017  
1391 **16**(4): p. 1506-1514.
- 1392 105. Yao Y, et al., *One-step SH2 superbinder-based approach for sensitive analysis of*  
1393 *Tyrosine phosphoproteome*. J Proteome Res, 2019. **18**(4): p. 1870-1879.
- 1394 106. Deng Z, et al., *Biphasic affinity chromatographic approach for deep tyrosine*  
1395 *phosphoproteome analysis*. Anal Chem, 2017. **89**(4): p. 2405-2410.
- 1396 107. Engholm-Keller K, L.M., *Improving the phosphoproteome coverage for limited*  
1397 *sample amounts using TiO<sub>2</sub>-SIMAC-HILIC (TiSH) p-peptide enrichment and*  
1398 *fractionation*. Methods Mol Biol, 2016. **1355**: p. 161-177.
- 1399 108. Kanshin E, et al., *Combined enrichment/enzymatic approach to study tightly*  
1400 *clustered multisite phosphorylation on Ser-rich domains*. J Proteome Res, 2018.  
1401 **17**(9): p. 3050-3060.
- 1402 109. Pieroni L, et al., *Enrichments of post-translational modifications in proteomic*  
1403 *studies*. J Sep Sci, 2019

- 
- 1404 110. Fukuda I, et al., *Optimization of enrichment conditions on TiO<sub>2</sub> chromatography*  
1405 *using glycerol as an additive reagent for effective phosphoproteomic analysis.* J  
1406 Proteome Res, 2013. **12**(12): p. 5587-5597.
- 1407 111. Hong YY, et al., *Hydrophilic phytic acid-functionalized magnetic dendritic*  
1408 *mesoporous silica nanospheres with immobilized Ti<sup>4+</sup>: A dual-purpose affinity*  
1409 *material for highly efficient enrichment of glycopeptides/p-peptides.* Talanta 2019.  
1410 **197**: p. 77-85.
- 1411 112. Luo B, et al., *Boronic acid-functionalized magnetic metal-organic frameworks via*  
1412 *a dual-ligand strategy for highly efficient enrichment of p-peptides and*  
1413 *glycopeptides.* ACS Sustain Chem Eng 2019. **7**(6): p. 6043-6052.
- 1414 113. Xu D, et al., *Highly selective SiO<sub>2</sub>-NH<sub>2</sub>@TiO<sub>2</sub> hollow microspheres for*  
1415 *simultaneous enrichment of p-peptides and glycopeptides.* Anal Bioanal Chem,  
1416 2017. **409**(6): p. 1607-1614.
- 1417 114. Xu D, et al., *Synthesis of bifunctional TiO<sub>2</sub>@SiO<sub>2</sub>-B(OH)<sub>2</sub>@Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub>*  
1418 *sandwich-like nanosheets for sequential selective enrichment of p-peptides and*  
1419 *glycopeptides for mass spectrometric analysis.* Anal Bioanal Chem, 2016. **408**(20):  
1420 p. 5489-5497.
- 1421 115. Xu D, et al., *Selective enrichment of glycopeptides/p-peptides using*  
1422 *Fe<sub>3</sub>O<sub>4</sub>@Au-B(OH)<sub>2</sub>@mTiO<sub>2</sub> core-shell microspheres.* Talanta, 2017 **166**: p.  
1423 154-161.
- 1424 116. Lin H, Yuan K, and Deng C, *Preparation of a TiO<sub>2</sub>-NH<sub>2</sub> modified MALDI plate for*  
1425 *on-plate simultaneous enrichment of p-peptides and glycopeptides.* Talanta, 2017  
1426 **175**: p. 427-434.
- 1427 117. Hughes CS, et al., *Single-pot, solid-phase-enhanced sample preparation for*  
1428 *proteomics experiments.* Nat Protoc, 2019. **14**(1): p. 68-85.
- 1429 118. Chouinard CD, et al., *Improved sensitivity and separations for p-peptides using*  
1430 *online liquid chromatography coupled with structures for lossless ion*  
1431 *manipulations ion mobility–mass spectrometry.* Analytical chemistry, 2018. **90**(18):  
1432 p. 10889-10896.
- 1433 119. Zhang Z, et al., *Single-Shot Capillary Zone Electrophoresis-Tandem Mass*  
1434 *Spectrometry Produces Over 4400 P-peptide Identifications from 220 ng Sample.*  
1435 Journal Proteo Res, 2019.
- 1436 120. Chen D, et al., *Capillary Zone Electrophoresis -Tandem mass spectrometry for*  
1437 *large-scale phosphoproteomics with the production of over 11,000 p-peptides*  
1438 *from the Colon Carcinoma HCT116 Cell Line.* . Analytical chemistry., 2019 **91**(3):  
1439 p. 2201-2208.
- 1440 121. Larsen MR, et al., *Highly selective enrichment of phosphorylated peptides from*  
1441 *peptide mixtures using titanium dioxide microcolumns.* Mol Cell Proteomics, 2005  
1442 **4**(7): p. 873-886.
- 1443 122. Gonzalez-Sanchez MB, et al., *Attempting to rewrite History: challenges with the*  
1444 *analysis of histidine-phosphorylated peptides.* Biochem Soc Trans 2013. **41** (4): p.  
1445 1089–1095.

- 
- 1446 123. Humphrey SJ, et al., *High-throughput and high-sensitivity phosphoproteomics with*  
1447 *the EasyPhos platform*. Nat Protoc, 2018. **13**(9): p. 1897-1916.
- 1448 124. Yang XQ and Yan X, *Urea-modified metal-organic framework of type MIL-101(Cr)*  
1449 *for the preconcentration of phosphorylated peptides*. Microchimica Acta, 2016.  
1450 **183**(7): p. 2235-2240.
- 1451 125. Hong Y, et al., *Dendritic mesoporous silica nanoparticles with abundant Ti<sup>4+</sup> for*  
1452 *p-peptide enrichment from cancer cells with 96% specificity*. Anal Chem, 2018  
1453 **90**(12): p. 7617-7625.
- 1454 126. He XM, et al., *Graft modification of cotton with phosphate group and its*  
1455 *application to the enrichment of p-peptides*. J Chromatogr A, 2017 **1484**: p. 49-57.
- 1456 127. Salimi K, et al., *Ti (IV) attached-phosphonic acid functionalized capillary monolith*  
1457 *as a stationary phase for in-syringe-type fast and robust enrichment of p-peptides*.  
1458 Biomed Chromatogr, 2019. **33**(6): p. e4488.
- 1459 128. Zhang K, et al., *Phytic acid functionalized Fe<sub>3</sub>O<sub>4</sub> nanoparticles loaded with Ti(IV)*  
1460 *ions for p-peptide enrichment in mass spectrometric analysis*. Mikrochim Acta,  
1461 2019. **186**(2): p. 68.
- 1462 129. Zhang L, et al., *Magnetic mesoporous carbon composites incorporating*  
1463 *hydrophilic metallic nanoparticles for enrichment of p-peptides prior to their*  
1464 *determination by MALDI-TOF mass spectrometry*. Microchimica Acta, 2017.  
1465 **184**(2): p. 547-555.
- 1466 130. Zhang L, et al., *Soft-template synthesis of hydrophilic metallic zirconia*  
1467 *nanoparticle-incorporated ordered mesoporous carbon composite and its*  
1468 *application in p-peptide enrichment* Rsc Advances, 2016. **6**: p. 30014-30020
- 1469 131. Jabeen F, et al., *In-Tip lanthanum oxide monolith for the enrichment of*  
1470 *phosphorylated biomolecules*. Anal Chem, 2017. **89**(19): p. 10232-10238.
- 1471 132. Li K, et al., *In-tube solid-phase microextraction capillary column packed with*  
1472 *mesoporous TiO<sub>2</sub> nanoparticles for p-peptide analysis*. Electrophoresis, 2019. **40**: p.  
1473 2142-2148.
- 1474 133. Long XY, et al., *Controllable preparation of CuFeMnO<sub>4</sub> nanospheres as a novel*  
1475 *multifunctional affinity probe for efficient adsorption and selective enrichment of*  
1476 *low-abundance peptides and p-peptides*. Anal Chem, 2017. **89**(19): p.  
1477 10446-10453.
- 1478 134. Zou X, Jie J, and Yang B, *Single-step enrichment of N-glycopeptides and*  
1479 *p-peptides with novel multifunctional Ti<sup>4+</sup>-immobilized dendritic polyglycerol*  
1480 *coated chitosan nanomaterials*. Anal Chem, 2017. **89**(14): p. 7520-7526.
- 1481 135. Xie Y and Deng C, *Designed synthesis of a "One for Two" hydrophilic magnetic*  
1482 *amino-functionalized metal-organic framework for highly efficient enrichment of*  
1483 *glycopeptides and p-peptides*. . Sci Rep, 2017. **7**(1): p. 1162.
- 1484 136. Wu Y, et al., *Core-shell structured magnetic metal-organic framework composites*  
1485 *for highly selective enrichment of endogenous N-linked glycopeptides and*  
1486 *p-peptides*. Talanta, 2018. **190**: p. 298-312.

- 
- 1487 137. Wang J, et al., *Facile synthesis of hydrophilic polyamidoxime polymers as a novel*  
1488 *solid-phase extraction matrix for sequential characterization of glyco- and*  
1489 *phosphoproteomes*. *Anal Chim Acta*, 2016. **907**: p. 69-76.  
1490 138. Sun N, et al., *Magnetite nanoparticles coated with mercaptosuccinic acid-modified*  
1491 *mesoporous titania as a hydrophilic sorbent for glycopeptides and p-peptides prior*  
1492 *to their quantitation by LC-MS/MS*. *Mikrochim Acta*, 2019 **186**(3): p. 159.  
1493

---

1494 **Figure Legends**

1495 **Graphical abstract:** Schematic diagram for p-peptide enrichment strategies.  $Ti^{4+}$   
1496 lab-in-syringe polydopamine coated three-dimensional porous graphene aerogel  
1497 sorbent carrying immobilized titanium (IV) ions (denoted as  $Ti^{4+}@PDA@GA$  [53]),  
1498 Phos-PAD: p-peptide paper-based analytical devices [72], graphene  
1499 oxide-trimethyl-2-methacroyloxyethyl ammonium chloride-titania (GO-META- $TiO_2$ ) [64].  
1500 PolyMAC: (polymer-based metal ion affinity capture) [86, 87]. Phosphotyrosine antibody  
1501 cocktails [102]. Phosphotyrosine-imprinted polymer with  $TiO_2$  [100]. IMAC-antibody  
1502 (IMAC with phosphotyrosine antibody) [15]. High pH and pH step wise elution [15].  
1503 Gradient elution: 100 mM  $NH_4HCO_3$  (pH 9.2-11.3 step gradient and pH adjust by  
1504 ammonia [16].  $Ti^{4+}@PDA@GA$ ) Adapted with permission [53]. Copyright 2018, Springer  
1505 Nature. Phos-PAD) Adapted with permission [72]. Copyright 2019, Elsevier.  
1506 GO-META- $TiO_2$ ) Adapted with permission [64]. Copyright 2019, Elsevier.

1507

1508 **Figure 1** Sample preparation workflows for phosphoproteomics (a). The key steps are  
1509 “protein extraction”, “proteolytic digestion”, “p-peptide enrichment” and “fractionation”  
1510 [11]. The latest developments for sample preparation workflows aim to minimise the  
1511 number of processing steps, using robust and reproducible component methods.  
1512 Common strategies for p-peptide enrichment (b) [88]. (c) Main steps for affinity-based  
1513 p-peptide enrichment techniques. (d) Improvements for p-peptide enrichment. b)  
1514 Adapted with permission [88]. Copyright 2017, the Royal Society of Chemistry.

1515

1516 **Figure 2** Schemes for the creation and use of three novel enrichment materials: a)  
1517 MagG@PEI@PA- $Ti^{4+}$ , which can adsorb  $53.5 \mu g mg^{-1}$  p-peptide with 90% recovery, and is  
1518 sensitive to concentrations as low as  $0.8 fmol.\mu l^{-1}$  [49], b)  $Ti^{4+}@PDA@GA$ , aerogel,  
1519 formed from graphene oxide (GO), is used in a lab-in-syringe methodology that  
1520 preferentially enriches p-proteins ( $1300-1345 \mu g mg^{-1}$  vs  $4.8-160 \mu g mg^{-1}$ ), can adsorb  
1521 up to  $1340 \mu g mg^{-1}$ , and is sensitive to concentrations as low as  $2 fmol.\mu l^{-1}$  [37], and c)

---

1522 magG@PD-Hf<sup>4+</sup>, which showed sensitivity to concentrations as low as 0.08 fmol.μl<sup>-1</sup> [47].  
1523 All figures adapted with permission: [49] Copyright 2018, American Chemical  
1524 Society; [37] Copyright 2018, Springer Nature; [47] Copyright 2016, Elsevier.

1525

1526 **Figure 3** Schemes for the creation and use of two novel MOAC formats: a)  
1527 Fe<sub>3</sub>O<sub>4</sub>@H-fTiO<sub>2</sub> a functionalized TiO<sub>2</sub> layer nanoparticle, with larger pore volumes (0.52  
1528 cm<sup>3</sup>g<sup>-1</sup>) and higher surface area (144.71 m<sup>2</sup>g<sup>-1</sup>) than existing TiO<sub>2</sub> magnetic spheres,  
1529 showed a p-peptide:peptide selectivity ratio of up to 1:10000, and sensitivity down to  
1530 0.2 fmol.μl<sup>-1</sup>, (α-casein, BSA, HeLa cell) [64]. b) GF-TiO<sub>2</sub>-GO showed sensitivity down to  
1531 0.1 fmol.μl<sup>-1</sup> and provided an unbiased mono-multi p-site peptide distribution in  
1532 concentrations of up to 0.2 μg.mg<sup>-1</sup>spheres (β-casein, BSA, non-fat milk and human  
1533 serum) [67]. Figures adapted with permission: [64] Copyright 2018, Elsevier; [67]  
1534 Copyright 2018, the Royal Society of Chemistry.

1535

1536 **Figure 4** Schemes for the creation and use of 3 IMAC/MOAC hybrid materials: a)  
1537 Fe<sub>3</sub>O<sub>4</sub>@n SiO<sub>2</sub>@m SiO<sub>2</sub>/TiO<sub>2</sub>-Ti<sup>4+</sup> is sensitive to p-peptides from concentrations as low as  
1538 40 fmol.μl<sup>-1</sup>, has high surface area (179.3 m<sup>2</sup>g<sup>-1</sup>) and a selectivity ratio of 1:50, with an  
1539 adsorption capacity of 133 mg/g (β-casein, BSA, non-fat milk) [76]; b) TiO<sub>2</sub>@DOTA-Zr  
1540 showed sensitivity of as low as 10 μmol.μl<sup>-1</sup>, and a selectivity ratio of 1:10 (β-casein, BSA,  
1541 nonfat milk, human serum) [77]; and c) G@TiO<sub>2</sub>@mSiO<sub>2</sub> showed a sensitivity of 1  
1542 fmol.μl<sup>-1</sup> and a selectivity ratio of 1 to 1000 (α- or β- casein, BSA, human serum) [79].  
1543 Adapted with permission: [76] Copyright 2017, Elsevier; [77] Copyright 2017, Elsevier;  
1544 [79] Copyright 2016, Elsevier.

1545

1546 **Figure 5** Typical workflow or schematic diagram of simultaneous N-glyco-peptide and  
1547 p-peptide (a-c). Magnetic materials of (a) SPIOs@SiO<sub>2</sub>@MOF (β-casein, BSA, IgG, rat  
1548 brain, rat liver) [109], (b) TiO<sub>2</sub>@SiO<sub>2</sub>-B(OH)<sub>2</sub>@Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> (β-casein, BSA, horseradish  
1549 peroxidase, defatted milk) [111]. Samples were incubated with materials for 30 min in

---

1550 loading buffer (50% ACN, 0.1% or 0.25% TFA, v/v), washed 3 times, and then eluted by  
1551 ammonia solutions (0.4 M or 10% wt%) after 30 min's treatment. (c) TiO<sub>2</sub>-NH<sub>2</sub> modified  
1552 MALDI plate ( $\beta$ -casein, BSA, horseradish peroxidase, human serum, human saliva) [113],  
1553 for which 5 min of incubation (50% ACN, 1% TFA, or 95% ACN, 0.1% TFA, v/v), after 5  
1554 times washing, DHB was added for direct LC-MS/MS analysis. Reproduced from [109]  
1555 Copyright 2019, American Chemical Society; [111] Copyright 2016, Springer Nature; [113].  
1556 Copyright 2017, Elsevier.

1557

### 1558 **Supporting files**

#### 1559 **Tables**

1560 **Table S1** Comparison of p-peptide enrichment by immobilized metal ion affinity  
1561 chromatography (IMAC) for different metal ions (A) and different supporting ligands (B).

1562 **Table S2** Comparison of p-peptide enrichment by metal oxide affinity chromatography  
1563 (MOAC) for different metal oxides (A) and different supporting ligands (B).

1564 **Table S3** Comparison of hybrid composites for p-peptide enrichment.

1565 **Table S4** Novel materials for simultaneous enrichment of p-peptide (P) and glycopeptide  
1566 (G).

1567

**Table 1. Existing formats for metal based p-peptide enrichment.**

<b>Technique/ Example format</b>	<b>Incubation</b>	<b>Washing</b>	<b>Elution</b>	
<b>MOAC TiO<sub>2</sub> magnetic beads</b>	(1) TiO <sub>2</sub> material pre-condition according to manufacturer's instructions, eg. wash with condition buffer;  (2) Desalted peptides incubate with magnetic TiO <sub>2</sub> beads for 30 min with the presence of 1M lactic acid or glycolic acid;  (3) P-peptide was captured and retained by TiO <sub>2</sub> .	non-p-peptide washed using high ACN buffer	3% ammonium solution	GE healthcare
<b>IMAC (Phos-Select Iron Affinity Gel beads pack into microcolumn)</b>	(1) Microcolumn preparation: gel beads were pipetting into special tips; the tips were then place into centrifuge adaptor; and conditioned before use.  (2) Peptides were incubated with gel beads for 30 min.	Unbound peptides removed using wash buffer  250 mM acetic acid with 30% ACN	Bound peptides were released into 250 mM acetic acid pH 3.0 in 30% ACN	Sigma
<b>Phos-tag micropipette</b>	(1) Prepare Phos-tag agarose gel and phosphate-affinity micropipette-tip;	Wash three times with	Elute by syringe with buffer solution 0.10 M Na <sub>4</sub> P <sub>2</sub> O <sub>7</sub> /0.10	[82, 83]

<b>tip</b>	(2) Condition the Phos-tag tip; Draw sample. gently into the micropipette-tip by using 1 ml syringe and agarose beads in suspension was kept for a few seconds, repeat 5 times;	washing buffer and water once using syringe	M CH <sub>3</sub> COOH (pH 7.0) or 0.1 M aqueous HCl, 2% aqueous (v/v) TFA, 5% aqueous NH <sub>3</sub> , or 0.10 M EDTA/NaOH (pH 7.0)
<b>PolyMAC reagent (-Ti or -Fe)</b>	(1) Synthesis of PolyMAC reagent; (2) Peptides incubate with PolyMAC reagent for 5 min, and add capture buffer; (3) Transfer mixture to spin column with washed resin and incubate for 10 min with agitation; (4) Wash with loading buffer and incubate for 5 min with agitation;	Washed with washing buffer and water	400 mM ammonium hydroxide [86, 87]

1569 **Table 2 Example p-peptide enrichment protocols published in the last five years, these can form user guides due to full and detailed**  
 1570 **protocols considering theoretical and practical aspects of workflow design and application**

<b>Sample and Study</b>	<b>p-peptide enrichment</b>	<b>Analyte/Starting amount</b>	<b>Fractionation</b>	<b>Number of p-peptides</b>	<b>Key Developments</b>	<b>Reference</b>
Breast cancer subtypes from patient-derived mouse xenograft models (CPTAC) consortium  Multiplex analysis using TMT 10 plex for comparative analysis	Ni-NTA IMAC	300 micrograms 5% directed to Proteomic analysis and 95% to phosphoproteomic analysis	High-pH reverse HPLC, prior to IMAC	35,000 p-peptides/ experiment, on average	Application to tissue blocks and mammalian samples.  Multiplex analysis for higher throughput	[17]
Tomato Plants  Quantitative proteomic analysis using dimethyl labelling	PolyMAC-Ti	200 microgram aliquots	High-pH reverse HPLC of enriched p-peptides	30,000 unique p-peptides from tomato leaves	Protocol for with universal application to plant samples	[21]
EGF stimulation of human U-87 glioblastoma cells  Quantitative proteomic analysis by Label Free Quantification	MOAC Titansphere Phos-TiO	200 micrograms (originally developed for 1 mg)	None	~20,000 p-peptides, comprising 16,021 accurately localized phosphorylation sites	EasyPhos eliminates requirement for peptide desalting before p-peptide enrichment	[123]

HLA class I-associated p-peptides	IMAC Fe(III) ± NTA-Fe(III)	submicrogram levels of peptide material	None	161 p-peptides	Improved sensitivity Reduced nonspecific binding, improved peptide recoveries	[24]
Prostate cancer (xenograft tumours)  Quantitative proteomic analysis by Label Free Quantification	pTyr immunoprecipitation and TiO <sub>2</sub>  pSer.pThr MOAC-TiO <sub>2</sub>	50-150 mg starting wet tissue	SCX to remove multiply charged peptides prior to enrichment of pSer, PThr  MOAC-TiO <sub>2</sub>		85% of the p-peptides identified are pTyr  Demonstration of the value of experimental design, use of replicates in analysis of clinical samples	[36]

1571 pY peptides using specific phosphotyrosine antibodies and TiO<sub>2</sub>. We also describe the enrichment of phosphoserine/threonine (pST)  
1572 peptides using strong cation exchange (SCX) followed by TiO<sub>2</sub>.

1573 **Supporting Tables**1574 **Table S1A** Comparison of p-peptide enrichment by immobilized metal ion affinity chromatography for different metal ions

Materials	Sensitivity	Selectivity	Mono	Multi	Real sample matrix	Instrumentation	Ref
		$\beta$ -casein:BSA digests (n:n)					
Fe <sub>3</sub> O <sub>4</sub> @PDA- Nb <sup>5+</sup>	2 fmol	1:100	5	11	non-fat milk	MALDI-TOF/TOF (AB Sciex 5800)	[46]
Fe <sub>3</sub> O <sub>4</sub> @PDA-Ti <sup>4+</sup>	2 fmol	1:100	5	9	non-fat milk		
Fe <sub>3</sub> O <sub>4</sub> @PDA-Zr <sup>4+</sup>	80 fmol	1:100	4	7	non-fat milk		
Fe <sub>3</sub> O <sub>4</sub> @PDA-Ce <sup>4+</sup>	2 fmol	1:50	5	6	non-fat milk		
Fe <sub>3</sub> O <sub>4</sub> @PDA-Ga <sup>3+</sup>	20 fmol	1:100	4	7	non-fat milk		
Fe <sub>3</sub> O <sub>4</sub> @PDA-Y <sup>3+</sup>	80 fmol	1:50	2	5	non-fat milk		
Fe <sub>3</sub> O <sub>4</sub> @PDA-In <sup>3+</sup>	200 fmol	1:50	4	5	non-fat milk		
Fe <sub>3</sub> O <sub>4</sub> @PDA-Fe <sup>3+</sup>	200 fmol	1:50	5	6	non-fat milk		
Fe <sub>3</sub> O <sub>4</sub> @PDA- Nb/Ti binary composite	2 fmol	1:1000	8	11	human serum, nonfat milk	MALDI-TOF-MS	[48]
Urea-modified (Cr)-Amine based affinity	MIL-101 100 fmol/ $\mu$ L	1:200	-	-	human serum	MALDI-TOF-MS	[124]

1575

1576 **Table S1B** Comparison of p-peptide enrichment by immobilized metal ion affinity chromatography for different supporting ligands

Materials	Sensitivity (fmol/ $\mu$ L)	Selectivity $\beta$ -casein:BSA digests (n:n)	Real sample matrix	Instrumentation	Ref
Ti <sup>4+</sup> @PDA@GA	30	1:200	milk, human serum	MALDI-TOF-MS	[53]
	0.08	1:500	non-fat milk, human serum	MALDI-TOF-MS (AB Sciex 5800)	[49]
magG@PDA-Hf <sup>4+</sup>	0.08	1:1000	human saliva	MALDI-TOF-MS and Orbitrap	[50]
magG@PDA-Sn <sup>4+</sup>	0.2 *	1:5000*	HeLa cell	ESI-MS/MS (Q-Exactive) MALDI-TOF-MS	[125]
DMSNs@PDA-Ti <sup>4+</sup>	0.05	1:500	human serum	(AB Sciex 4800 plus) MALDI-TOF-MS	[56]
magSiO <sub>2</sub> @SiO <sub>2</sub> @PDA@Ti(IV)	0.1	1:500	human serum, saliva	(Voyager-DE PRO) MALDI-TOF/TOF	[47]
Fe <sub>3</sub> O <sub>4</sub> @mSiO <sub>2</sub> -Ti <sup>4+</sup>		1:500	non-fat milk, human serum	(AB Sciex 5800) MALDI-TOF (Axima TOF <sup>2</sup> ), and RPLC-ESI-MS/MS (AB Sciex	[91]
Fe <sub>3</sub> O <sub>4</sub> @SiO <sub>2</sub> -PLP-Ti <sup>4+</sup>	10 fmol,			TripleTOF5600+ )	

	-	1:100	yeast	Orbitrap Elite hybrid ion trap-Orbitrap-MS	[55]
Fe <sub>3</sub> O <sub>4</sub> @silica@GMA@IDA@Ti <sup>4+</sup>		1:100	non-fat milk, human	MALDI-TOF-MS	[126]
CF-NH <sub>2</sub> -AZO-p(VPA-x)-Ti <sup>4+</sup>	1 × 10 <sup>-4</sup>		serum, rat brain	and LC-ESI-MS/MS	
Ti (IV)@poly(VPA-co-EDMA)		1:1500	human serum	MALDI-TOF-MS	[127]
monolith	0.001			(Voyager - DE PRO)	
Ti-PA-MNPs	8 × 10 <sup>-4</sup>	1:2000	rat liver	MALDI-TOF-MS	[128]

1577 \*: data from α-casein : BSA; (1 M: 100 pmol/μL)

1578

1579

**Table S2A** Comparison of p-peptide enrichment by metal oxide affinity chromatography (MOAC) for different metal oxides

Materials	Sensitivity (fmol/ $\mu$ L)	Selectivity $\beta$ -casein:BSA digests (n:n)	Real sample matrix	Instrumentation	Ref
In <sub>2</sub> O <sub>3</sub> , SnO <sub>2</sub> , NiO, Co <sub>3</sub> O <sub>4</sub>	-	-	human embryonic kidney cell line	Orbitrap XL or Orbitrap Elite	[43]
MoO <sub>3</sub> /GO	$1 \times 10^{-3}$	1:1000	nonfat milk, human serum	MALDI-TOF/TOF (AB Sciex 5800)	[60]
Fe <sub>3</sub> O <sub>4</sub> @PDA@Er(btc)	$2 \times 10^{-5}$	1:500	human serum	MALDI-TOF/TOF (AB Sciex 5800)	[61]
zirconia/magnetic composites	1.5	1:500	nonfat milk, human serum	MALDI-TOF-MS/MS (AB Sciex 4800 plus)	[129]
Zirconia/OMC	1.5	1:300	non-fat milk	MALDI-TOF-MS/MS (AB Sciex 4800 plus)	[130]
In-Tip La <sub>2</sub> O <sub>3</sub> monolith	0.25	1:4500	egg yolk, human serum	MALDI-TOF/TOF-MS (Ultraflex-II)	[131]

1580

1581 **Table S2B** Comparison of p-peptide enrichment by metal oxide affinity chromatography (MOAC) for different supporting ligands

Materials	Sensitivity	Selectivity	Real sample matrix	Instrumentation	Ref
		$\beta$ -casein:BSA digests (n:n)			
TMA-microchips (TiO <sub>2</sub> )	0.4	1:100	egg white	MALDI-TOF-MS	[71]
	0.2 *	1:10000*	HeLa cell	MALDI-TOF-MS (AB Sciex 4800 plus) and	[62]
Fe <sub>3</sub> O <sub>4</sub> @H-fTiO <sub>2</sub>				RPLC-ESI-MS/MS	
	-	1:100	yeast	Orbitrap Elite hybrid ion trap-Orbitrap	[66]
mGCB@TiO <sub>2</sub>				MS	
GO-META-TiO <sub>2</sub>	10	1:100	chicken egg white	MALDI-TOF-MS	[64]
	-	-	cytochrome C, lysozyme,	LTQ Velos ion-trap MS	[69]
CIM-OH-TiO <sub>2</sub>			human serum		
	$1 \times 10^{-5}$	1:100	non-fat milk, human	MALDI-TOF-MS	[65]
GF-TiO <sub>2</sub> -GO			serum		
mesoporous TiO <sub>2</sub> in - tube solid - phase microextraction column	10	1:100	non-fat milk	MALDI-TOF-MS	[132]

1582 \*: data from  $\alpha$ -casein : BSA

1583

**Table S3** Comparison of hybrid composites for p-peptide enrichment

Materials	Sensitivity (fmol/ $\mu$ L)	Selectivity $\beta$ -casein:BSA digests (n:n)	Real sample matrix	Synthesis	Instrumentation	Ref
TiO <sub>2</sub> /Bi/Fe/Zr	$4 \times 10^{-4}$	1:1000	Hela cell	sol-gel method	MALDI-TOF/TOF (AB Sciex 5800)	[58]
B <sub>0.15</sub> F <sub>0.15</sub> TNs	$2 \times 10^{-3}$	1:1200	human liver	sol-gel method	MALDI-TOF/TOF (AB Sciex 5800)	[59]
MnFe <sub>2</sub> O <sub>4</sub> MAMs	1	1:500	non-fat milk, human serum	solvothermal route	MALDI-TOF-MS (AB Sciex 4800)	[75]
CuFeMnO <sub>4</sub> nanospheres affinity probe	20	1:100	nonfat milk, A549 cells, human saliva, human serum	solvothermal route	MALDI-TOF-MS (AB Sciex 4800)	[133]
Fe <sub>3</sub> O <sub>4</sub> @PDA-Ti/Nb	2	1:1000	non-fat milk, human serum	-	MALDI-TOF-MS	[48]
Fe <sub>3</sub> O <sub>4</sub> @nSiO <sub>2</sub> @mSiO <sub>2</sub> /TiO <sub>2</sub> -Ti <sup>4+</sup>	4	1:50	nonfat milk	magnetic /mesoporous silica	MALDI-TOF/TOF (AB Sciex 5800)	[78]
Fe <sub>3</sub> O <sub>4</sub> @H-TiO <sub>2</sub> @f-NiO	$2 \times 10^{-4*}$	1:5000*	non-fat milk/human		MALDI-TOF	[63]

			serum/HeLa cell		(AB Sciex 4800 plus)	
PAA-Ti/TiO <sub>2</sub> composite	2	1:1000	human serum, -		MALDI-TOF/TOF (AB Sciex 5800)	[80]
TiO <sub>2</sub> @DOTA-Zr	1×10 <sup>-7</sup>	1:10	nonfat milk, human serum	macrocyclic ligand	MALDI-TOF/TOF	[79]
magG/PD/(Zr-Ti)O <sub>4</sub>	4.0 × 10 <sup>-5</sup>	1:8000	mouse brain tissue	magnetic/graphene	MALDI-TOF MS	[76]
		weight ratio				
G@TiO <sub>2</sub> @mSiO <sub>2</sub>	1	1:1000;	human serum	magnetic/graphene/ mesoporous silica	MALDI-TOF MS and MALDI-TOF/TOF	[81]
Al <sub>2</sub> O <sub>3</sub> - TiO <sub>2</sub> / ZrO <sub>2</sub> /CeO <sub>2</sub> / La <sub>2</sub> O <sub>3</sub>	10	1:1000;	human serum	co-precipitation	MALDI-TOF/TOF (Ultraflex-I)	[77]

1585 \*: data from α-casein : BSA

**Table S4** Novel materials for simultaneous enrichment of p-peptide (P) and glycopeptide (G)

Materials	Sensitivity		Selectivity		Real sample matrix	Instrumentation	Ref
	(fmol/ $\mu$ L)		standard digests <sup>a</sup> (n/n)				
	P	G	P	G			
SiO <sub>2</sub> -NH <sub>2</sub> @TiO <sub>2</sub>	0.16	2	1/500	1/500	human serum albumin	MALDI-TOF (AB Sciex 5800)	[113]
					human serum/saliva,	MALDI-TOF	[114]
TiO <sub>2</sub> @SiO <sub>2</sub> -B(OH) <sub>2</sub> @Fe <sub>3</sub> O <sub>4</sub> @ TiO <sub>2</sub>	0.8 - 8	2.5 - 25	1/1000	1/50	defatted milk	(AB Sciex 5800)	
	0.08 -				human serum/saliva,	MALDI-TOF	[115]
Fe <sub>3</sub> O <sub>4</sub> @Au-B(OH) <sub>2</sub> @mTiO <sub>2</sub>	0.8	2 - 20	1/1000	1/100	defatted milk	(AB Sciex 5800)	
						MALDI-TOF	[116]
TiO <sub>2</sub> -NH <sub>2</sub> modified MALDI plate	8	20	1/200	1/100	human serum/saliva	(AB Sciex 5800)	
						MALDI-TOF	[134]
CS@PGMA@IDA-Ti <sup>4+</sup>	0.1	0.1	1/500	1/100	human IgG, mouse liver	(AXIMA-CFP plus)	
						MALDI-TOF	[135]
Fe <sub>3</sub> O <sub>4</sub> @PDA@UiO-66-NH <sub>2</sub> (Zr <sup>3+</sup> )	0.02	0.2	1/500	1/100	human serum	(AB Sciex 5800)	
						MALDI-TOF (AB Sciex	[51]
MagG@PEI@PA-Ti <sup>4+</sup>	0.1*	0.5 <sup>#</sup>	1/5000*	1/1000 <sup>#</sup>	human serum	4800 plus)	

						MALDI-TOF (AB Sciex	[111]
Mag-MSMs@PEI-PA-Ti <sup>4+</sup>	0.2*	0.5 #	1/5000*	1/1000#	human serum, HeLa cell	4800 plus)	
						MALDI-TOF	[136]
Fe <sub>3</sub> O <sub>4</sub> @MIL-100(Fe)	0.1	0.1	1/50	1/20	human saliva	(AB Sciex 5800)	
						MALDI-TOF	[137]
co-PAN@Ti <sup>4+</sup>	4	100	1/50	1/50	human serum	(AB Sciex 5800)	
						MALDI-TOF/TOF (AB	[138]
Fe <sub>3</sub> O <sub>4</sub> @mTiO <sub>2</sub> -MSA	50	10 <sup>-3</sup>	1/800	1/100	human saliva	Sciex 5800)	
					rat brain, rat liver,	MALDI-TOF	[112]
SPIOs@SiO <sub>2</sub> @MOF	10 <sup>-4</sup>	10 <sup>-5</sup>	1/400	1/500	mouse liver	(AB Sciex 5800)	

1587 a: β-casein/BSA for P; horseradish peroxidase/BSA for G. \*: data from α-casein/BSA; #: data from IgG/BSA.

1588 PGMA: poly glycidyl methacrylate.